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1. 
PREFACE 
The object of this thesis is to examine in detail some aspects 
of phenylalanine metabolism in the infant and child. Specifically, 
the effects of a reduced dietary intake of phenylalanine are examined 
in the normal infant and the infant with phenylketonuria. 
Chloramphenicol, a known inhibitor of protein synthesis in 
the bacterial cell, is investigated for its action on amino acid 
metabolism and bone marrow morphology of infants and children. The 
interaction of phenylalanine and chloramphenicol is discussed in 
relation to protein synthesis and the antibacterial properties of 
the drug. 
Many of the abnormal findings in animals deprived of a single 
essential amino acid, such as phenylalanine, or given large doses of 
chloramphenicol, are analogous to the abnormalities found in children 
with the syndrome kwashiorkor. This analogy is pursued in the 
discussion, using both the relevant literature available and the 
findings described in Part II of the thesis. One important question 
raised is whether the ratio of essential amino acids contained in the 
diets at present force fed to the premature infant might be less than 
optimal for normal growth and brain development. 
2. 
The young infant with phenylketonuria can be successfully 
treated by restricting his dietary intake of phenylalanine. Dietary 
management of two phenylketonuric infants diagnosed early is des- 
cribed, and the importance of a relative deficiency of phenylalanine 
as a critical limiting factor in protein synthesis is discussed. 
One possible method for controlling blood phenylalanine concentra- 
tions in the young phenylketonuric infant with a less critical 
dietary regimen is suggested. 
3. 
HISTORICAL INTRODUCTION 
The identification of carbon- dioxide or "fixed air" by 
Joseph Black (1728- 1799), Professor of Chemistry and Physic at 
Edinburgh was perhaps the first step towards a scientific evalua- 
tion of nutrition (Kent, 1950). Daniel Rutherford (1749- 1819), 
a pupil of Black, obtained his doctorate in Medicine from the 
University of Edinburgh for his "Dissertatio inauguralis de Aere 
Fixo Dicto, aut Mephitico" (Rutherford, 1772). In his thesis, 
he described the presence of another gas in the air which would 
not support life or fire and named it "aer málignus" or noxious 
air. There is argument as to whether Rutherford or Priestley (1772) 
was the first to describe this gas we now call nitrogen but McKie 
gives Rutherford the credit. The name nitrogen was given to the 
gas by Chaptel (1790) because it formed the radical of nitric acid. 
Antoine Lavoisier continued work based on Black's original 
findings and describes experiments on human subjects in which he 
showed that oxygen is consumed and carbon dioxide evolved during 
respiration. He further demonstrated that the quantity of oxygen 
used increases by some 50% above the basal level after a meal (the 
specific dynamic action of food) and that exercise also increases 
oxygen consumption. 
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It was Magendie (1783 -1855) who first demonstrated that nitro- 
genous compounds were essential constituents of the diet (Magendie, 
1816). This conclusion was reached from experiments in which dogs 
fed solely a carbohydrate (sugar) or fat (olive oil) diet survived 
only a few weeks. Vitamins were unsuspected at this time and it is 
probable that vitamin deficiency played a major part in the death 
of these dogs. The experiments were the first long -term feeding 
experiments and were the forerunner to those described later in this 
thesis. Magendie expanded his work on dogs and made the distinction 
between nitrogenous and non -nitrogenous foods in his "Elementary 
Compendium of Physiology for the Use of Students" (1829). 
The importance of nitrogen containing foods for the formation 
of blood and tissue was first recognized by Justus von Liebig. I 
quote from the English edition of his book, "Animal Chemistry, or 
Organic Chemistry in its Applications to Physiology and Pathology," 
*1842) (p. 95): 
..., the substances of which the food of man is composed may 
be divided into two classes; into nitrogenized and non -nitrogenized. 
The former are capable of conversion into blood; the latter incapable 
of this transformation. 
Out of those substances which are adapted to the formation of 
blood are formed all the organized tissues." 
5. 
Liebig also drew attention to urea as the nitrogenous end - 
product of protein metabolism excreted in the urine. The name 
protein, derived from the Greek work "proteios" meaning "primary" or 
"first," was first used by the Dutch chemist Gerrit Jan Mulder (1802- 
1880) to describe nitrogenous compounds linked to sulphur and phos- 
phorus (Mulder, 1839). 
Nitrogen balance studies were developed by Carl Voit (1831- 
1908) who had been a pupil of Liebig in Munich. He found in his long- 
term study of healthy mature animals that their nitrogen intake and 
output was equal, giving a state of equilibrium. He went on to demon- 
strate the protein- sparing action of carbohydrate and fat (Voit, 1869). 
It was from this time on that the intensive study of nutrition 
and protein metabolism were to develop in many countries throughout 
the world. There is yet no final answer to what constitutes ideal 
nutrition but a great deal is now known of the quantitative and quali- 
tative aspects of the problem. 
6. 
QUANTITATIVE ASPECTS OF PROTEIN METABOLISM 
Another Professor of Chemistry at Edinburgh, Playfair, first 
reported (1853 and 1865) the dietary requirements for protein in 
different groups of the population. He found that the normal labourer 
required 184 G of protein per day while the sedentary worker required 
only 57 G per day. The diet he recommended for the average healthy 
adult was one containing 119 G protein, 51 G fat, and 530 G carbo- 
hydrate. Results published by Voit (1881) and Atwater (1894) supported 
Playfair's findings although subsequent workers Swen (1901), Chittenden 
(1905), and Hlndhede (1913) claimed that intake of from 30 -55 G of 
protein per day were quite adequate. Cathcart (1921) and others noted, 
however, that there was a lowered resistance to disease in people 
maintained on low -protein diets. This observation is pertinent to 
this thesis and to present day observations on the syndromes of 
Kwashiorkor and marasmus which are the result of protein deficient diets. 
Watkin et al (1963) recommend 1 G protein /Kg /day for the average healthy 
young adult. 
Throughout infancy and childhood, while growth is taking place, 
there is retention of nitrogen in the body. If Voit had studied immature 
animals, his observations on nitrogen equilibrium would not have held 
true. The newborn and suckling periods of life are characterized 
by an extreme anabolic tendency with nitrogen retention. 
7. 
This can be demonstrated even when there is not enough food available 
to allow growth to take place. The starving newborn infant derives 
only 4 -5% of his total calorie requirement from protein breakdown, 
whereas the healthy adult male utilizes protein for about 20% of his 
metabolic needs (1lcCance and Strangeways, 1954). Normally, however, 
when food is provided, growth dominates and creates the great demand 
for protein and other nutrients which characterize the newborn period. 
Bunge (1898) related the growth rate of the young of different 
animal species to the percentage protein of the mother's milk. The 
higher the protein content found, the faster was the rate of growth 
for the species. A human baby retains 53% of the nitrogen from breast 
milk at 6 -8 days of age and an average of 22% over the first 6 months 
(Slater, 1961). Babies on cow's milk formula retain more nitrogen 
from the higher protein intake afforded. They do not, however, gain 
weight any faster than babies fed human milk. Although Bunge's 
results hold true for each species, one cannot increase the growth 
rate in man by feeding the higher protein milk of another mammal. 
There is as yet no complete answer to the comparatively simple problem 
of comparing the relative merits for human infants of breast milk and 
substitutes based on cow's milk (Platt et al, 1961). 
Protein requirements are generally thought of in terms of so 
many grams per kilogram of body weight per day. On this basis, the 
human infant requires 2 U /kg /day while the young rat will require as 
8. 
much as 20 G /kg /day. This intake of protein will maintain life and 
encourage growth but is not necessarily the optimum quantity. The 
intake of protein, which produces maximal growth rate, may not be 
optimal for health. Experiments performed by McCay et al (1935, 
1939) showed that in animals severe restriction of food sufficient 
to interfere with growth allowed the animal to live longer. Ross 
(1959, 1961) confirmed these findings and suggested that protein 
restriction may contribute to a longer life in rats. The problem as 
to what constitutes the optimum protein intake for the maintenance 
of health remains as yet unanswered. 
We have considered, thus far, only the quantity of dietary 
protein, assuming a standard nutritive value for all proteins. The 
nutritive quality of protein does vary widely according to its 
source in nature, which is in turn, related to the chemical structure 
of the protein. Amino acids are the building- blocks from which proteins 
are made. The nutritive quality of a protein is finally dependent 
on the ratio and type of amino acids which go to make up that particular 
protein. 
9. 
QUALITATIVE ASPECTS OF PROTEIN METABOLISM 
Willcock and Hopkins (1906) reported that complement of 
Tryptophan would prolong the lives of mice fed a tryptophan free 
diet. This was the first demonstration that a dietary deficiency 
of an individual amino acid could seriously interfere with nutrition 
and health. 
The concept of dietary amino -acid balance was first introduced 
by Osborne and Mendel (1914). Their observations on the body 
requirements for a number of different amino -acids led them to 
conclude that the nutritive value of a protein was dependent upon 
the proportions of the individual amino -acids it contained (Osborne 
and Mendel, 1915). During the years that followed, new amino -acids 
were discovered and the group of eight which are essential or indis- 
pensible dietary constituents for man were described and evaluated, 
(Rose, 1936; Whipple, 1940; Cannon, 1947; Rose et al, 1954 a -b; 1955 
a -e; Rose and Wixom, 1955 a -b). 
At the same time, Block and Mitchell (1946 -47) developed the 
concept of Chemical Score to relate the nutritional value of a protein 
to its amino -acid composition. This score provided a means of 
predicting the nutritive quality of a protein. In essence, it compared 
10. 
the proportions of essential amino -acids in a protein with those 
found in whole egg protein. 
Concepts of relative nutritive values of proteins were further 
developed when it was realized how important was the ratio of 
essential to non -essential amino -acids (Harper and Kumta, 1959). If 
the ratio of amino -acids in a protein is such that a small amount 
of protein will provide each amino acid in the exactly required 
amounts, it is very efficient and will have a high Protein Efficiency 
Ratio or Chemical Score. On the other hand, if the ratio of amino - 
acids in a protein is such that a surplus of several amino -acids must 
be ingested to ensure an adequate intake of one or more of the others, 
then the protein will have a lower Protein Efficiency Ratio or 
Chemical Score. 
Holt and co- workers at New York University have studied the 
amino -acid requirements of the normal and premature infants (Pratt 
et al, 1955; Snyderman et al, 1955, 1959 a -d; Holt, 1960). A synthetic 
diet in which nitrogen is supplied as a mixture of 18 L -amino acids 
in proportions present in breast milk was fed to infants. The quantity 
of the specific amino acid under consideration was reduced and replaced 
with an isonitrogenous quantity of glycine until a point was reached 
at which nitrogen retention and gain in weight suffered. Table I is 
summary of the findings of Holt et al and Albanese (1959). 
11. 
Table 1 







(1.65 gm protein /kg) 
Arginine 0 43 
Histidine 35 24 
Isoleucine (90) * 75 
Leucine 150.229* * 135 








cystine) (65) * 32 
Threonine 60 51 
Tryptophan 16-22*** 16 
Valine 105 80 
*Data of Albanese et al.° (N furnished as degraded protein or protein 
hydrolysate). 
** The usual leucine requirement did not exceed 150 mg /kg. One subject 
however required 229 mg /kg. 
* ** The usual requirement did not exceed 16 mg /kg. One subject required 
22 mg /kg. 
The values for the essential amino acid requirements 
would seem applicable to the experimental conditions under 
which they were determined, but they may.not be applicable 
to other situations. Furthermore, amino acid requirements 
are effected by the "balance" or pattern of the available 
amino acids of the diet. An unbalanced pattern may increase 
the requirement for one or another essential amino acid. 
Factors that spare essential amino acids will also affect 
the requirement; the intake of other calorigenic foodstuffs 
and of "unessential" nitrogen are of particular importance 
in this regard. 
(Holt, Jr., L.E., in Amino Acid and Protein Metabolism, 
Report of Thirtieth Ross Conference on Pediatric Research, 
Fomon, S.J., Ed., Columbus, Ross Laboratories, 1959, p. 13.) 
12. 
The effects of omitting one essential amino -acid from the 
diet for only a few hours can b detected (Elman, 1939; Geiger, 
1947 -48; Cannon et al, 1947). Within one day (in young growing 
animals), this results in loss of appetite and growth failure, and, 
in mature animals, in a severe negative nitrogen balance.(Rose, 1933; 
Frazier et al, 1947; Kepkowsky, 1948). The animal is immediately 
unable to utilize the other dietary amino -acids except as a source 
of energy. These findings stem from the fact that there is essen- 
tially no storage of amino -acids in the body. It is this inability 
of the body to compensate, even for a short time for a deficiency 
of a single amino acid that makes amino -acid balance so critical and 
makes the growing infant so sensitive to alterations in the amino - 
acid pattern of his diet. Omission of most other essential nutrients, 
including vitamins and minerals for much longer periods of time, 
has little immediate effect on growth and food intake and may have 
none at all until body reserves are depleted. 
Sidransky and co- workers in a series of studies (Sidransky, 
1958 a -b, 1960, 1961, 1962, 1964 a -b, and Lyman and Wilcox, 1963) have 
studied in detail the effect of individual amino -acid deficiencies 
on the laboratory animal. Table II summarises the chemical and morpho- 
logic changes induced in young rats by force feeding purified diets 
devoid of single essential amino acids for three to eight days (Sidransky 
& Verney, 1964). The animals fed a diet deficient in phenylalanine 
13. 
developed a periportal fatty liver, excess hepatic glycogen and 
atrophy of the pancreas, submaxillary gland, gastric mucosa, thymus 
and spleen within eight days of commencing the diet. Sidransky 
concluded that single deficiencies of all essential amino acids 
except arginine and leucine can produce most of the features of the 
kwashiorker -like experimental model. The results of experiments 
in which animals were force -fed diets containing plant proteins of 
poor quality and quantity (Deo and Ramalingaswami, 1960; Sidransky, 
1960) were almost identical with those found with single essential 
amino acid deficiencies. No mention of bone marrow or peripheral 
blood changes resulting from isolated amino acid deficiencies is made 
in any of the animal studies quoted or in Holts' study of infants. 
One purpose of this thesis is to explore further the concept 
of amino acid imbalance in the young infant with particular emphasis 
on the effect of a dietary deficiency of phenylalanine on amino 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ANAEMIA AND PROTEIN MALNUTRITION 
In the tropics, cases of anaemia refractory to treatment 
with iron, vitamin B12, or folic acid are numerous. They are 
especially common during pregnancy, infancy and childhood (Woodruff, 
1960). Hansen (1956) showed that the chief limiting nutrients in 
low protein diets that produce kwashiorkor are the amino acids. A 
study by Brock and Autret (1952) of protein malnutrition in Africa 
showed that the syndrome of kwashiorkor which is a result of protein 
malnutrition was associated with a mild normocytic or macrocytic 
anaemia. When parasitic infections were present, the anaemia could 
be severe. Woodruff (1951 and 1955) has also described such anaemia 
in association with protein malnutrition. 
Some understanding of the mechanisms whereby protein malnutrition 
may cause anaemia was obtained from the experimental evidence provided 
by Whipple and Madden (1949) and Yale et al (1951). They demonstrated 
that haemoglobin may be synthesized from plasma proteins. In dogs, 
they showed that plasma could supply proteins from which the depleted 
animal could manufacture new haemoglobin and that 100 G casein digest 
enabled 25 -40 G of new haemoglobin and plasma protein to be produced. 
This study was really a sophisticated demonstration of Liebig's 
original observation. The work of Wizet and Robscheit -Robbins (1950) 
16. 
indicated (at the reticulocyte stage) the red cell is able to incor- 
porate plasma proteins into itself or synthesize plasma proteins from 
amino acids. Furthermore, a deficiency or abnormality of plasma 
protein, delayed the maturation of red precursors. 
The anaemia, as stated, may be normocytic or slightly macrocytic. 
Mean cell volumes (MCV) are commonly at the upper limit of normal 
and the mean corpuscular diameter (MCD) is often increased above the 
normal range which results in a corresponding reduction in the mean 
corpuscular average thickness (MCAT) (Woodruff, 1955). The broadening 
and thinning of erythrocytes, described by Trowell (1949) as dimorphic 
anaemia might well be due to this type of cell where the thinness gives 
the appearance of hypochromia while broadening makes them appear macro - 
cytic (Woodruff, 1961). 
Pigs fed protein deficient diets show a reduced haemoglobin and 
red cell count accompanied by a fall in unsaturated iron -binding 
capacity and a rise in serum iron (Platt et al, 1964). The limiting 
factor for haemoglobin synthesis in these animals was shown clearly 
to be protein. 
One type of anaemia which is probably directly related to protein 
deficiency has been observed in children with severe kwashiorkor 
(Viteri et al, 1964). These children come from the highland areas of 
Guatemala where there is no hookworm and where vitamin B12 and folic 
acid deficiencies are uncommon. The anaemia is normocytic or slightly 
17. 
macrocytic and not usually severe although the bone marrow is severely 
hypoplastic, especially for the erythroid series. When the children 
are treated with milk alone, the bone marrow rapidly becomes hyper - 
plastic and a good reticulocyte response is observed within a week. 
This type of anaemia appears to be due to an arrest in erythrocyte 
formation at a very early stage in haematopoiesis because of the 
severe deficiency of protein. 
Vacuolizations of early erythroblasts has been reported in 
African children during the early stages of marasmus and kwashiorkor, 
(Kondi and Foy, 1964). This change in marrow morphology disappears 
with increased protein intake. Sometimes the vacuoles develop later 
in the illness and are associated with intercurrent infection; vacuo- 
lization is then accompanied by hypoplasia of the erythroid series. 
Kondi and Foy comment that "In marasmus and kwashiorkor, vacuolization 
may be associated with a dietary deficiency of phenylalanine or other 
amino -acids for low protein intake is usually regarded as an aetiological 
factor in these conditions." They demonstrated similar morphologic 
changes in the erythroblasts of bäboons made deficient in riboflavine. 
The riboflavine deficiency might well have acted through an interference 
with amino acid metabolism because the animals had an abnormal amino 
aciduria. Reference to a possible deficiency of phenylalanine is based 
on the findings of Sherman et al (1964) who reported anaemia and red 
cell precursor maturation arrest with vacuolization in an infant with 
phenylketonuria on a low phenylalanine diet. 
18. 
Tryptophan deficiency in animals will produce anaemia (Albanese 
et al, 1953). Supplements of tryptophan will prevent this anaemia 
even when the diet of the animals is poor. 
There is then good evidence linking protein deficiency states 
to a normocytic or macrocytic anaemia. The bone marrow is hypoplastic 
and the few red cell precursors present may show cytoplasmic vacuoles. 
This anaemia in children can be reversed by protein feeding. 
19. 
INFECTION AND PROTEIN MALNUTRITION 
Severe protein deficiency interferes with the resistance of 
the body to infection (Scrimshaw et al, 1939). Mild protein defi- 
ciency has little or no effect on the adult animals' resistance to 
infection (Metcoff et al, 1948 -49). A degree of protein deprivation 
which will not affect the adult response to infection might, however, 
seriously interfere with the response in the growing infant. The 
high mortality which is seen in young children in technically un- 
developed countries is due directly to the synergism of malnutrition 
and infective disease (Scrimshaw, 1961). 
Rost reaction to an infectious agent involves the study of a 
great many factors. Genetic variations in host resistance, the 
virulence of the infectious agent, host age, sex and coexistant 
disease render the interpretation of the effect of protein deficiency 
very difficult in man. Moreover, the host may have previously developed 
sufficient immunity from contact with the infecting agent so that he 
is no longer susceptible. 
Effect on Antibody Response: Madden and Whipple (1940) found that 
dogs fed low protein diets had poor antibody responses to a variety 
of antigens. Miller et al (1940) demonstrated that the same dogs 
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were much more susceptible to infections. When the dogs were fed a 
good protein diet, their antibody responses and their response to 
infection returned to normal. Protein deficiency in the rabbit 
reduces its capacity to produce agglutinins to Salmonella (Cannon et 
al, 1943) and to the Pauçmococcus (Wissler, 1947 a). A group of rats 
normally resistant to a particular strain of pneumococcus lost this 
resistance when fed a protein deficient diet (Wissler, 1947 b). The 
antibody response to the infection was very poor but it improved 
markedly when a mixture of amino acids was fed. Loss of antibody 
response in rats to injected sheep red blood cells can be directly 
correlated to the duration of protein deprivation (Benditt et al, 1949). 
Evidence for a delayed or poor antibody response to a number of 
antigens in man in the presence of a poor dietary intake of protein 
has been reported. Wohl et al (1949) noted a markedly delayed anti- 
body response to typhoid vaccine in 88 patients with low serum albumin 
levels. Cannon (1944) had reported the same findings in a group of 
15 patients with low total serum proteins. A fifteen year old girl 
reported by Krebs (1946) showed no response to thyroid vaccine while 
No 
she had a total protein of 3.1 G /100 ml. serum of which 2.0 G /ml.was 
albumin. 
More recently, Olarte et al (1956) reported a retarded response 
to diphtheria antitoxin in five two -year old Mexican children with 
severe malnutrition. Budiansky and Da Silva (1957) found that twelve 
21. 
of fifteen children with kwashiorkor showed practically no antibody 
response to typhoid vaccine. 
The antibody is an important body defence against the invading 
pathogen but it is only one of several defence mechanisms which lose 
their efficiency in the face of protein deficiency. It is a res- 
ponse, however, which is readily measured and thus lends itself to 
study. Phagocytic activity is equally important in body defence and 
the lack of leucocytic response to infection in children with kwashior- 
kor is probably a significant factor in their reduced resistance to 
infection (Trowell et al, 1954; Scrimshaw and Behar, 1961). 
22. 
PHENYLALAQINE AND PROTEIN SYNTHESIS 
Phenylalanine is a nutritionally essential amino acid. Schulze 
and Barbieri (1879) first isolated phenylalanine from the sprouts 
of lupine. They later isolated it from acid and alkaline hydrolysates 
of squash seed proteins and showed it to be a constituent of protein 
(1883). The empirical formula was established by these same authors 
and they demonstrated that oxidation yielded benzoic acid and that 
dry distillation yielded what appeared to be phenylethylamine (1881). 
Erlenmeyer and Lipp (1882) synthesized phenylalanine from 
phenylacetaldehyde and Schulze and Barbieri (1883) proved that their 




Fig. 1 Phenylalanine g- amino/3 -phenylpropionic acid) 
Phenylalanine, like all the other amino acids, is not stored in 
the body. Once it has been absorbed from the intestine into the portal 
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circulation one of several pathways of metabolism is open to it. 
First, in the growing infant, it is essential for the formation of many 
types of new protein as well as the continuous renewal of the existing 
pool of body protein. The functions and types of protein required 
by the infant are many, e.g., haemoglobin, antibody, digestive enzymes, 
plasma proteins, hormones and body tissue protein. 
A second pathway is the conversion of phenylalanine to tyrosine 
which in turn is necessary for the production of melanin, the pigment 
which affects skin, hair and eye colour, noradrenaline and adrenaline 
as well as the thyroid hormones (iodotyrosines). It is a block to 
this metabolic pathway which results in the clinical syndrome of 
Phenylketonuria and will be discussed in detail later. 
A third possible route is the conversion of phenylalanine into a 
source of energy by its breakdown and entry into the glycogenic and 
ketogenic pathways of the liver. Small quantities of phenylalanine 
appear normally in the urine. This loss is insignificant in amount 
unless there is renal overflow from high blood levels of phenylalanine 
such as that found with phenylketonuria. 
The presence of an asymmetric carbon atom in phenylalanine, as 
in all other amino acids except glycine confers the property of stereo - 
isomerism. D- and L- optically active forms of phenylalanine are 
present in dietary proteins but it is the L -form which is of major 
importance in protein metabolism. 
24. 
Genetic Control of Protein Manufacture: The function and character 
of each protein molecule is dependent upon the arrangement of indi- 
vidual amino acids within the molecule and upon the incorporation of 
prosthetic substances, e.g., Iron in haemoglobin. Given a supply 
of raw materials (namely amino acids) and a factory, a set of blue- 
prints or code must be available if the necessary proteins are to 
be manufactured. 
Work of recent years has thrown considerable light on the way 
in which the code for each protein is stored in a structural gene 
which is formed from deoxyribonucleic acid (DNA). The code or genetic 
information stored in DNA is transmitted to the protein- making machinery 
Of the cell:, so that a specific nucleotide sequence in DNA gives rise 
to a unique amino acid sequence in the polypeptide chain of a protein. 
WE now known that ribonucleic acid (RNA) participates in this process 
as a messenger between DNA and the protein, (Jacob and Monod, 1961; 
Brenner et al, 1961). Protein is made on the ribosome or on groups 
of ribosomes linked by the chain of messenger RNA (m -RNA) to form a 
polysome, (Borsook et al, 1952, Warner et al, 1963; Gierer, 1963). 
The ribosomes as seen by electron microscopy are small dark particles 
attached to the cytoplasmic membrane and consist of RNA and protein. 
DNA normally occurs as a double- stranded molecule resembling a 
ladder that has been twisted into a helix. The sides of the ladder 
consist of alternating units of the sugar deoxyribose and a simple 
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phosphate compound. The rungs of the ladder are attached to the deo- 
xyribose units and each rung consists of a purine and a pyrimidine 
base, either adenine(A) linked to thymine(E), or guanine( %) linked 
to cytosine(C). This is the model proposed by Watson and Crick (1953). 
The molecule of RNA is generally a single stranded structure 
that contains the sugar ribose in place of the deoxyribose sugar found 
in DNA. Four bases are linked to the ribose units, three of which are 
identical with those in DNA, the fourth being uracil(U) which replaces 
the thymine found in DNA. 
The relation between DNA, messenger RNA and protein is illustrated 
schematically in Fig. 2 in which portions of the base or nucleotide 
sequence and amino acid chains are shown as lengths of paper tape. 
DNA ITTC TTT CAA AGA TAA AAG CGC ATA TCA AAA CAG GGGG 
Step 1 
m -RNA AAG AAA GUU UCU AUU DUC GCG UAL. AGU UUU GUC CCC 
PROTEIN 
Step 2 
glu lys cys phe tyr leu gly leu met phe arg pro 
Fig. 2 - Two -step transcription of genetic code. RNA nucleotidyl 
transferase, which catalyzes the DNA- dependent synthesis of RNA, 
is the key enzyme in the transcription of the genetic message 
from DNA to RNA (step 1). The code read -out step (step 2) can 
be considered as a translation from the four character language 
of proteins. m -RNA stands for messenger RNA. 
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It takes a base sequence of three to code one amino acid, 
(Crick et al, 1961). Nirenberg and Matthaei (1961) demonstrated that 
a triplet of uridine base (UUU) in m -RNA was the probable code for 
the amino acid phenylalanine. More recently, the m -RNA code for each 
amino acid has been demonstrated to be degenerate in that there is 
more than one correct base sequence for an individual amino a6id. 
Thus, (UCU) uridine with cytosine has also been found to code for 
phenylalanine (Ochoa, 1964). 
The significance of uridine as the m -RNA code for phenylalanine 
will be further discussed in relation to chloramphenicol toxicity. 
Before phenylalanine can be united with other amino acids on the 
ribosome or protein factory, it is first activated by being coupled 
with a source of energy, adenosine triphosphate (ATP) in the presence 
of a specific enzyme (Hoagland et al, 1956). The activated phenyla- 
lanine is then attached to a specific RNA called soluble RNA or 
transfer RNA (Hoagland, 1955). Each different amino acid in the cyto- 
plasm of the cell is "recognized" and attached to a specific transfer 
RNA. The transfer RNA's carry the amino acids to the ribosome, where 
they are joined in proper order to form a protein. The transfer RNA's 
are released intact to pick up more amino acid molecules (see Fig. 3) 
Zubay, 1963. 
It is evident that the transfer of information from the basic 









MODEL OF PROTEIN SYNTHESIS IN POLYSOMES 
(AFTER ZUBAY) 
Fig. 3 The triplet code is read on the ribosome as 
it "moves along" the messenger RNA chain. 
Transfer RNA brings the amino acid named by 
the codeiinto position on the ribosome. They 
amino acid forms a peptide linkage with the 
peptide chain which is being formed and the 
transfer RNA is released. 
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m -RNA molecule to the final protein is the mechanism of translation of 
genotype into phenotype. From this we can argue that the primary effect 
of genes in an organism is to control the biochemistry of the cells of 
that organism. This concept was first postulated by Garrod (1909). 
A single gene mutation with alteration of a base pair in the DNA 
helix should result in the replacement of one amino acid in a protein 
by another different amino acid. This hypothesis was verified in the 
case of sickle -cell anaemia in man. Glutamic acid, present in normal 
haemoglobin is replaced by valine which results in the sickling properties 
of the red blood cell (Ingram, 1961). Thirty different haemoglobin 
molecules, the result of genetic controlled substitutions of amino acids, 
have now been described (Hirschhorn, 1964). 
Phenylalanine is incorporated into many different protein mole- 
cules according to the codes contained in the genetic material. If no 
phenylalanine is available for protein synthesis then normal protein 
cannot be manufactured. Should there be interference with the code for 
phenylalanine at the gene level or at the ribosome, then again normal 
protein cannot be produced by the cell. 
Part of my later arguments will be to show that a dietary deficiency 
of phenylalanine, or a block to the incorporation of phenylalanine 
into protein will produce a situation identical with that produced by 
severe protein malnutrition. 
29. 
THE EFFECTS OF CIiLORA IPB NICOL ON BACTERIAL AND 
MAMMALIAN PROTEIN SYNTHESIS 
Chloramphenicol is an antibiotic which preferentially inhibits 
protein synthesis in a number of organisms (Gale and Folkes, 1953; 
Brock, 1961; Feingold, 1963). Studies on the mechanism by which 
chloramphenicol inhibits protein synthesis indicate that inhibition 
occurs at a stage subsequent to the attachment of amino acids to 
soluble RNA (s -RNA) and in relation to the ribosomal assembly of amino 
acids on messenger RNA (m -RNA), (DeNoss and Novelli, 1956; Lacks and 
Gross, 1960; Nathans et al, 1962). Rendi and Ochoa (1962) suggest 
that chloramphenicol might interfere with the attachment of m -RNA to 
ribosomes. The steric configuration of chloramphenicol in solution 
is very similar to uridine 5' phosphate and it may be that chloram- 
phenicol interferes with uridine coding at the ribosome, (Jardetsky, 
1963; Jardetsky and Julian, 1964). 
The earlier investigations of Woolley and others showed that the 
action of chloramphenicol can be partially antagonised by certain amino 
acids and, in particular, by phenylalanine (Bergman and Sicker, 1952; 
Molho and Mof1 o, 1951; Truhaut et al, 1951; Woolley, 1950). Woolley 
suggested that the antibiotic can be regarded as an analogue of 
phenylalanine and the possibility that it can substitute for or displace 
this amino acid at some stage in protein synthesis cannot be ruled out. 
30. 
The similarity of the chemical structure of the amino acid and anti- 
biotic is apparent (Fig. 4). Indeed, Yamada and Matsuo (1962) have 
used L- phenylalanine as a basis for the synthesis of chloramphenicol. 
Protein synthesis in mammalian cells or mammalian cell -free 
systems is much more resistant to inhibition by chloramphenicol than 
it is in microbial systems. This difference in sensitivity is most 
apparent in cell -free systems where cellular permeability is not a 
factor. Complete inhibition of protein synthesis in E. coli cell -free 
systems can be obtained with 0.15//mole chloramphenicol /ml. of reaction 
mixture (Nirenberg and Matthei, 1961). Practically no inhibition of 
protein synthesis in many mammalian cell -free systems had been demonstrated 
with chloramphenicol concentrations up to 5- 10/ífmoles /ml. reaction 
mixture (Von Ehrenstein and Lipmann, 1961). Inhibition of protein 
synthesis in the intact mammalian cells had been obtained only with 
concentrations of chloramphenicol much in excess of that required to 
inhibit bacteria (Allen and Schweet, 1962; Forsook et al, 1957; Britman 
and Webster, 1958; LePage, 1953; Rendi, 1959; Wang, 1961). Von Ehrenstein 
and Lipman (1961) suggest that the difference in sensitivity may be due 
to the presence in bacteria of an extra, chloramphenicol sensitive 
step, involved in the transfer of amino acids to ribosomes. 
During the past few years, however, it has become apparent that 
under appropriate conditions chloramphenicol will inhibit mammalian 
protein synthesis. AMbrose and Coons (1961) were able to inhibit antibody 
C H2OH 
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synthesis by lymph node fragments when chloramphenicol (0.15 /mole /m1) 
was present in the culture medium. Svéhag (1964) found inhibition of 
19S antibody formation in vitro with this concentration of antibiotic. 
Inhibition of protein synthesis in human bone marrow cultures was 
shown by Djordjevic and Szybalski (1960) at similar low concentrations 
of chloramphenicol. Weisberger and Wolfe (1964) demonstrated a sup- 
pression of antibody synthesis and prolonged survival of skin homografts 
in animals treated with chloramphenicol. They further demonstrated 
the sensitivity of a rabbit reticulocyte ribosome system to the inhi- 
bitory action of chloramphenicol. These observations are in accord 
with the suggestion that protein synthesis in intact mammalian cells 
may be susceptible to chloramphenicol inhibition only at a time when 
new m -RNA is being attached to ribosomes. More mature cells may be 
resistant because m -RNA already attached to ribosomes is not accessible 
to chloramphenicol inhibition. 
Rubin et al, 1960, demonstrated increased concentration of iron 
and an increased saturation of iron binding globulin in the serum of 
patients treated with chloramphenicol probably the results of suppressed 
haemoglobin synthesis. Collip et al, 1965, found inhibition of glucose 
6 phosphatase activity in the livers of ducks treated with chloramphenicol 
and have shown that this effect can be prevented by simultaneous 
administration of phenylalanine. Straub and Ullman (1957) report that 
the antibiotic inhibits synthesis of amylase by pancreatic tissue. 
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Certain other clinical observations indicate that chloramphenicol 
may inhibit protein synthesis by mammalian cells. For example, Saidi 
et al, 1961, found that administration of chloramphenicol to patients 
with pernicious anaemia in relapse prevents the reticulocyte response 
which is normally obtained with vitamin B12. The production of 
vacuoles in the cytoplasm of bone marrow red cell precursors associated 
with anaemia and a reduced retículocyte response during the course 
of chloramphenicol therapy (Saidi and Wallerstein, 1960; Saidi et al, 
1961; Rosenbach et al, 1960; McCurdy, 1961) might well be a further 
manifestation of suppressed protein synthesis. 
The ability of chloramphenicol to inhibit protein synthesis in 
mammalian cells may have relevance to the production by this drug of 
fatal aplastic anaemia. Abnormal ribosomal material and RNA accumulates 
in cells exposed to chloramphenicol, Gale, 1963. It may be that 
prolonged use or high dosage of the drug could result in absolute 
inhibition of normal ribosome or m -RNA formation, and produce aplasia 
of the red and, or white cell, precursors. Inherant genetic factors 
may influence the drug's action on the bone marrow cells of the indi- 
vidual host and account for individual susceptibility to chloramphenicol 
toxicity. Immature infants are particularly susceptible to chloram- 
phenicol toxicity. A clinical picture called the "Gray- baby" syndrome 
was produced in newborn and premature infants on chloramphenicol 
therapy. The syndrome has practically vanished since a lower recommended 
dose of the antibiotic has been employed for this age group. 
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It is thus evident that chloramphenicol has an effect on a number 
of different mammalian tissues. Part of my thesis will be to assess 
the effect of chloramphenicol on host amino acid metabolism and 
observe the interaction of the antibiotic and phenylalanine in the 
clinical and laboratory situation. 
35. 
PHENYLALANINE METABOLISM AND PHENYLKETONURIA 
The relationship between gene, enzyme and clinical abnormality 
first postulated by Garrod (1909) was clearly demonstrated for the 
first time in the disease phenylketonuria. Folling (1934) described 
10 patients who excreted phenylpyruvic acid and were mentally 
deficient. Jervis (1939, 1940) proved the condition was transmitted 
by a single autosomal recessive gene, and showed that large amounts 
of phenylalanine accumulated in the blood and spinal fluid of these 
patients-. The name phenylketonuria was introduced by Penrose and 
Quastel (1937) but the disease has been variously known as imbecillitas 
phenylpyruvica, Folling's disease and phenylpyruvic oligophrenia 
(Bickel, 1954). Jervis (1947, 1953) pin -pointed the defect and 
demonstrated that the liver of these patients failed to hydroxylate 
phenylalanine to tyrosine. The genetic defect results in a severe 
deficiency of the enzyme phenylalanine hydroxylase. 
Phenylalanine Hydroxylase: The main pathway of degradation of 
phenylalanine begins with a conversion to tyrosine, catalysed by a 
specific hydroxylating enzyme (Udenfriend and Cooper, 1952; Mitoma et 
al, 1956; Mitoma, 1956; Kaufman, 1957). This enzyme, called phenyla- 
lanine hydroxylase, catalyses a reaction involving molecular oxygen 
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which is irreversible. It occurs in the liver and catalyses hydro- 
xylation of phenylalanine at the para position in the presence of 
molecular oxygen, reduced TPN (tri- phosphopyridine nucleotide) and 
a folic acid derivative (Kaufman and Levenberg, 1959)(Fig. 5). 
Phenylalanine hydroxylase consists of two fractions (Kaufman and 
Levenberg, 1959) a labile one found only in the liver and a stable one 
which is found in many body tissues; only the former is lacking in 
phenylketonuria. 
The hydroxy group may be added to the aromatic ring of phenyl- 
alanine, either in the para- or the ortho- position. Normally, the 
para- position is favoured, so that tyrosine (p- hydroxyphenylalanine) 
is the major product of the oxidation of phenylalanine. Small amounts 
of ortho- hydroxy derivatives are found in the urine of normal indi- 
viduals but very large amounts occur in the phenylketonuric (Armstrong 
and Shaw, 1955). The basic defect in. phenylketonuria is then the 
lack of enzymatic activity for the para- oxidaticn of phenylalanine. 
Since this major pathway for the utilization of phenylalanine is 
blocked, phenylalanine and some of its metabolites accumulate and more 
phenylalanine is diverted to the ortho- hydroxy pathway, normally a 
minor route. High plasma concentrations of phenylalanine are charac- 
teristic of the disease (15 -63 mg /100 ml plasma). The normal values 
for phenylalanine concentration in the plasma are 1--4 mg /100 ml. 
Phenylalanine also accumulates in the cerebrospinal fluid and is 























































































large amounts of deaminated derivatives are found in the urine. These 
derivatives include phenylpyruvic acid, (Jervis, 1950), 4- hydroxy- 
phenylacetic acid (Armstrong et al, 1955), phenylacetyl glutamine 
(Woolf, 1951) and phenylethylamine. 
Abnormalities of tryptophan metabolism are regularly encountered 
in phenylketonuria. There is diversion of tryptophan metabolism from 
the nicotinic acid pathway and the serotonia pathway (Pare, et al, 
1958) more of the tryptophan being transaminated with the formation of 
indolepyruvic, indolelactic and indoleacetic acids (Armstrong and 
Robinson, 1954); indoxyl compounds are also formed and there is indi- 
canuria. The cause of the abnormal tryptophan metabolism is not 
established. Possibly, the increased transamination of phenylalanine 
has a stimulating effect on other transaminations, or the abnormal 
metabolites of phenylalanine may inhibit the serotonia and nicotinic 
acid pathways. 
Fig. 6 summarises the metabolic pathways discussed in this and 
the previous chapter. Also shown are the sites of metabolic block 
found in Tyrosinosis and Alcaptonuria. 
Clinical Features and Management: The incidence of phenylketonuría 
in Britain was calculated to be between 2 and 6 per 100,000 (Munro, 1947) 
while in American, the incidence of the disease is about 1 in 25,000 births 
39. 
METABOLISM OF PH NYLALANINE AND TYROSINE 
The metabolism of phenylalanine and tyrosine and the points at which metabolic impairment 
occurs in phenylketonuria, tyrosinosis, and alcaptonuria are summarized below. 
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(Holt and Snyderman, 1964). Improved diagnostic survey methods may 
show higher figures than those quoted. Kennedy in a report to the 
New England Pediatric Society (March, 1965) described 29 cases of 
phenylketonuria detected in Massachusetts by the Guthrie test (Guthrie, 
1962). Capillary blood samples of all infants born in Massachusetts 
were tested at 4 days and again at 4 weeks of age. The incidence of 
phenylketonuria for the period 1963 -1965 was 1 in 9,000 births. All 
but one of the cases reported by Kennedy had elevated blood levels 
of phenylalanine by the fourth day of life. Sex incidence of the 
disease is equal. 
In the untreated case, mental retardation is generally evident 
by the age of 6 months. Seizures and other neurologic abnormalities, 
lack of pigmentation of hair and skin, and eczema may occur. The 
majority of patients are idiots, a few are imbeciles, and rare patients 
have borderline intellectual development. Waisman and Harlow (1965) 
have produced experimental phenylketonuria in infant rhesus monkeys 
fed 3 G L- phenylalanine per kg of body weight per day. This intake of 
L- phenylalanine depresses phenylalanine hydroxylase activity and results 
in mental retardation with grand mal convulsions in the animals. 
Pathologically, the only evidence of the disease is retardation 
of myelination of the brain (Alvord et al, 1950). The precise nature 
of the alterations induced in the developing brain is not known. 
Dietary management of phenylketonuria has recently been described 
in detail in a Report to the Medical Research Council of the Conference 
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on Phenylketonuria (1963) and by Clayton et al, 1965. Low phenylalanine 
casein hydrolysate preparations are now commercially available and 
greatly facilitate the management of the diet. Adequate control of 
therapy depends on meeting, but not exceeding the phenylalanine require- 
ment and, at the same time, meeting the caloric and other nutritional 
requirements (Paine and Hsia, 1957). Previous estimates of an adequate 
'intake of phenylalanine for the young infant have been too low. 
Brimblecombe et al (1961) reported "...that in the first year of life, 
while growth is rapid, the.basic requirements of phenylalanine are 
relatively higher in mg /kg body weight than at older ages. Excessive 
restriction of phenylalanine intake at this stage may lead to subnormal 
levels of the plasma pehnylalanine, with loss of weight, vomiting, 
listlessness, and a generalised eczematous rash. Mental development 
is also retarded during these episodes." 
Three deaths are known to have occurred in phenylketonuric 
children with these symptoms. At least one fatal case had megaloblastic 
anaemia (Royston and Parry, 1962). Sherman et al (1964) reported 
anaemia, with maturation arrest of red cell precursors and failure to 
thrive in a premature phenylketonuric infant with low plasma levels of 
phenylalanine following treatment. 
The fine control of the disease thus becomes extremely important 
and the intake of phenylalanine must be carefully assessed for the 
individual patient. At present, this means regular estimation of the 
serum concentration and adjustment of the dietary phenylalanine intake 
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accordingly. Proper management of phenylketonuria is not possible if 
some accurate method of measuring blood levels of phenylalanine is 
not available. Urinary phenylpyruvic acid excretion ceases when the 
plasma phenylalanine concentration falls below 0.6 'moles per ml. 
(10 mg /100 ml). Estimation of urniary phenylpyruvic acid levels is 
then of little value when the concentration of phenylalanine in the 
plasma should be in the range 1.5 - 4.0 mg /100 ml to ensure optimum 
control of the disease. 
All the major biochemical abnormalities of phenylketonuria are 
reversed by the low phenylalanine diet (Knox, 1960). The amount of 
5- hydroxyindoleacetic acid in the urine is unchanged but the serotonif 
in the blood rises during treatment (Pare et al, 1953). Abnormal 
components in the B- globulin fraction of plasma in about half of 
the cases disappears with treatment and reappears when phenylalanine 
is reintroduced to the diet (Brown et al, 1955). 
Clinical improvement in behaviour and attention span with an 
improved pattern on electroencephalogram has been reported (Hsia et 
al, 1958). Motor performance improves as tremors and muscular hyper - 
tonicity decreases. The effect on intelligence is closely related to 
the age at which the corrective diet is instituted. If this is done 
in early infancy, a reasonable mentality can be expected. The results 
are less satisfactory the longer the delay in starting treatment (Horner 
and Streamer, 1959; Knox, 1960). There is as yet no good evidence on 
43. 
which to base the'decision to cease therapy. It has been suggested 
that 4 years is a reasonable age at which to stop treatment because 




CLINICAL AND EXPERIMENTAL FINDINGS 
Study 1: Effect of Phenylalanine Deficient Diet on Bone Marrow and 
Amino Acid Metabolism in Normal Infants. 
The present study is an investigation of the effects of a phenyl- 
alanine- deficient diet- in normal infants. Specifically, an attempt 
is made to correlate changes in amino acid metabolism with bone 
marrow changes. Previous reports of normal infants receiving diets 
deficient in phenylalanine make no mention of bone marrow changes or 
anaemia (dolt, 1958). There is one report of a megaloblastic type 
of erythroid maturation in a child with phenylketonuria on a phenyl- 
alanine- deficient diet (Royston and Parry, 1962). Sherman et al, (1964) 
reported anaemia and red cell precursor vacuolisation in a premature 
infant with phenylketonuria treated with a low phenylalanine diet. 
SUBJECTS: Six healthy premature infants between 12 and 39 days 
old (FO, SP, JO, IAA, MY, MU) were studied while they were in the 
hospital waiting to attain routine discharge weight. Their weights at 
the time of the study ranged from 1.6 to 2.4 kg. One 2.3 kg newborn 
infant (RU) with an extensive myelomeningocele, 2 full tern newborns 
weighing 3.2 kg (SU) and 4.5 kg (FR), and a 4 month old infant weighing 
7.5 kg (OB) were also studied. 
*Lofenalac, kindly supplied by Mead Johnson Co., Evansville, Ind. 
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DIETS: Diet I was a proprietary cow's milk preparation modified 
by the manufacturer to simulate human milk.* It was reconstituted to 
contain 1.5% protein, 7.0% carbohydrate, and 3.7% fat. It contained 
adequate supplements of vitamins and minerals. 
Diet III was a proprietary casein hydrolysate preparation from 
which the phenylalanine had been removed and to which certain amino 
acids had been added. Supplements of vitamins and minerals had been 
added as they had to Diet I. FAt and carbohydrate had been added so 
that the fat content of the phenylalanine- deficient feeding mixture 
was 2.7 %,carbohydrate 8.5%, and nitrogen equivalent to protein 2.25 %. 
The manufacturer's analysis records that each 32 ounces of the feeding 
mixture contains: 
Vit. A 1500 U.S.P. units 
Vit. D 400 " 
Vit. E 5 international units 
Vit. C 30 mg. 
Thiamine 1Cl 0.46 " 
Folic acid 0.05 " 
Biotin 0.03 " 
Riboflavin 1.8 " 
Niacinamide 4.0 " 
Pyridoxine í1C1 0.5 PB 
Calcium pantothenate 3.2 " 
Vit. B12 4.5g. 
Choline Cl 150.0 mg. 
Ferrous sulfate 15.0 " 
Diet II was the same proprietary phenylalanine -deficient diet 
complemented by L- phenylalanine added in amounts of 100 mg per kg of 
body weight per day. 
*Enfamil, idead Johnson Co., Evansville, Ind. 
46. 
DESIGN OF DIETARY SEQUENCES: Eight of the first 9 studies 
involved 48 -hour periods of ingestion of the deficient diet. In the 
ninth, FR ingested the deficient diet for 96 hours. Three infants 
(OB, SP, FO) were studied in the sequence of control Diet I, Control 
Diet II, deficient Diet III, and then Diet II. Two of these infants 
(SP2, F02), as well as 4 others (HA, HY, JO, FR), were given the 
deficient diet immediately after Diet I. 
Studies were carried out with SU, RU, and FR as subjects, 
in which the infants ingested Diet II for 6 to 14 days and then 
Diet III for 4 to 5 days. 
In various ancillary studies, supplements of other amino acids 
were added to the daily diets as follow: 
200 mg of L- methionine to Diet I for 3 days (RU); 
150 mg of L- valine and 1.0 g of L- valine to Diet II for 2 
days each (FO, JO); 
150 mg of L- alanine and 1.0 g of L- alanine to Diet II for 
2 days each (SP, HU) ; 
1.0 g of L- alanine to Diet III for 4 days and for 2 days 
(UU, JO); 
0.5 g of L- valine to Diet III for 2 days (JO). 
Studies were also carried out in UY when he ingested only 10% 
glucose in water for 24 hours. 
The feeding mixtures were offered to the infants 4 to 8 times 
a day in ad lib volumes. The volume of intake was estimated from the 
47. 
weights of the bottles before and after a feeding. During each study, 
the infants received no other nutritive materials. 
CLINICAL AND LABORATORY PROCEDURES: Infants were weighed at the 
beginning of each 24 -hour period. Urinary collections were made with 
constant urinary drainage, using external devices. Venous blood 
specimens for serum amino acid measurements and bone marrow material 
for examination were obtained at the end of diet periods. The last 
few amino acid studies, as noted below, utilized 'plasma from heparinized 
venous blood. Bone marrow was aspirated from the iliac crests and 
the tibias. Bone marrow specimens were also examined by an independant 
assessor who was unaware of the clinical or experimental state. All 
bone marrow specimens were stained with Wright- Giemsa stain with 
Prussian Blue. 
Microhematocrit and reticulocyte counts were performed by standard 
methods every 2 days during the period of study. Free amino acids in 
serum or plasma were measured by the Technicon Amino Acid Analyzer 
adaptation of the technique of Spackman, Stein and Moore (1958). Measure- 
ments were made of proline, glycine, alanine, valine, methionine, 
isoleucine, leucine, tyrosine, phenylalanine, lysine, histidine, and 
arginine. Total urinary free amino acids excreted by FO, FR, SU, RU, 
HU were determined by ion exchange on Dowex -50 columns using the ninhydrin 
end point of Moore and Stein (1954), and the individual amino acids 
48. 
excreted by all patients (except JO) were identified by 2 dimensional 
paper chromatography using the butanol- acetic acid -water system and 
the phenol -ammonia -water system (Smith, 1960 and Morrison, 1953). 
Estimates of change in individual amino acid excretion were made from 
the area and intensity of color of the spots on one dimensional paper 
chromatography. Urinary creatinines were measured, and all aliquots 
applied to paper represented a volume containing 4/4 of creatinine 
(Peters, 1962). 
RESULTS: Infants took the diets well. The mean daily intake 
was 245 ml /kg, and no significant difference was noted between the 
various diets. There were no changes in body weight, hematocrit, or 
reticulocyte count related to dietary changes. However, diarrhea, 
with excoriation of buttocks, was frequently noted when the children 
received either Diet II or III, both of which contained the casein 
hydrolysate preparation. All the infants thrived save for the child 
with the myelomeningocele whose study had to be interrupted when 
meningitis due to P. aeruginosa supervened. Concentrations of indi- 
vidual amino acids in the diets are recorded in Table III. 
The serum amino acid concentrations for the first 9 studies 
are shown in Table IV. The weight and age of the infants are also 
indicated. It may be seen that the initial ingestion of the casein 
hydrolysate mixture in either Diet II or Diet III was accompanied by 
gmfno 
an increased serum concentration of, \acids with the exception of phenyl- 














































































































































































































































































































































































































































































































































































































































































































































































































Effect of 48 Hour Dietary Periods on 'Morphologic Appearance of Boae:MA.row and Concentration of Amino Acids in Serum or Plasma. 
Diet I = modified cow's milk feeding mixture. Diet II = Diet'IIC plus 100 mg per kg per day of L- phenylalanine. 
Diet III = phenylalanine- deficient casein hydxiblysate feeding mixture. 
Subject Wt,kg Day Diet 
No. of vacuoles 





















HY 1.6 2 I 0 0 211 270 
21 days 1.7 4 III ++++ ++++ 278 306 
1.7 8 I 0 0 256 246 
HA 2.3 2 I 0 0 130 243 
40 days 2.4 4 III ++++ ++++ 295 219 
2.4 6 II 0 0 248 278 
J0[ 1.7 2 I 0 0 263 171 
12 days 1.6 4 III ++ ++ 188 269 
1.6 6 I 0 0 324 
F02 2.3 2 I 0 0 169 159 
34 days 2.4 4 III + + 287 186 
SP2 2.1 2 I 0 0 140 163 
37 days 2.2 4 III + + 294 174 
SP%, 1.7 2 I 0 0 151 187 
20 days 1.8 6 II 0 0 212 224 
1.9 8 III 0 ++ 221 177 
1.9 10 II 0 + 177 173 
FO! 1.8 2 I 0 0 178 183 
17 days 1.8 4 II 0 0 308 293 
1.9 6 III 0 ++ 239 200 
1.8 8 II 0 + 275 233 
FR 4.5 2 I 0 0 216 
7 days 4.5 6 III 0 ++ 396 
4.6 8 I 0 0 361 
OB 7.6 2 I 0 0 173 163 
4 mos. 7.5 4 II 0 0 404 106 
7.5 6 III 0 ++ 265 218 
7.5 8 II 0 + 190 226 
Diet 
Mean + I 
SEM II 
Proline 
178 + 13.3 
308 
III 258 + 14.7 
<701 P value I -III 
Glycine 
196 + 11.2 
208 
238 + 27.2 
NS 
Alanine 
317 ± 28.5 
551 
520 + 41.2 
L. O1 
Valine 
171 + 7.2 
414 
332 + 32.2 
<.01 
435 1911 29 
786 34 294 
615 21 16 
261 . 163 27 
482 484 207 
646 3q9 105 
426 19 27 
390 ;21 86 
365 13 41 
297 16r 25 
530 41/ 224 
228 13/ 27 
439 3S 190 
296 1E 32 
553 371 144 
433 300 122 
528 25. 84 
296 201 30 
657 43' 253 
458 31 204 
498 250 100 
201 15 
584 5C 116 
- 567 33" 85 
410 15 b. 18 
443 44:) 42 
583 36 55 
480 309. 44 
ilethionine 
27 ± 1.11 
146 
166 + 25.8 
<.01 
ISOleilcinE Leucine 
46+2.6;; 10+ 7.0 
73 ' 94 
















55 145 105 55 144 
63 177 38 6 365 
71 131 109 44 114 
121 161 51 129 
99 76 106 6 533 
54 127 75 27 301 
53 118 194 54 143 
47 129 95 297 
51 57 315 57 196 
49 73 38 84 
87 91 4 366 
33 91 80 41 91 
77 255 97 6 339 
40 93 103 34 122 
49 156 30 35 310 
51 168 36 8 289 
27 94 37 25 89 
47 120 117 41 124 
68 220 51 46 309 
47 146 27 9 234 
24 95 33 25 129 
50 94 65 38 153 
78 253 90 22 553 
85 237 50 72 538 
41 99 47 53 94 
102 207 104 92 185 
55 144 47 18 224 































L sine histidine Aro-inine 
99 + 12.1 45 + 2.7 121 ± 7.4 75 ± 3.0 86 + 6.9 
62 58 268 83 103 
70 + 12.4 10 + 2.2 356 + 38.7 92 + 9.9 91 + 7.5 
NS 4.01 iNS 
150 mg per day L- alanine added to Diet II in last period. 
! 150 mg per day L- valine added to Diet II in last period. 
[ Plasma utilized for amino acid determinations. 
51. 
amino acid excretion increased within 8 hours of beginning these diets 
and continued throughout the period, paralleling the increase in 
serum concentrations. The increase in total amino acid excretion was 
accounted for largely by increases in urinary valine, alanine, glycine, 
methionine, and histidine. No further increase in either serum or 
urinary amino acids was seen when the diet was changed from Diet II 
to Diet III. Indeed, there were some decreases in serum concentrations. 
At the end of the period of dietary deficiency, serum phenylalanine 
concentrations had fallen significantly in each patient. Final values 
were less in the smaller children (4- 94mols /1 vs. 18 and 2? nols /1). 
Phenylalanine concentrations after 48 hours of Diet III were slightly 
lower SP and RO when Diet III was preceded by Diet I (6 and 4 micro - 
moles per liter) than when Diet III was preceded by Diet II (9 and 8 
micromoles per liter). (Fig. 7). 
Two days on Diet III (phenylalanine- deficient) were sufficient to 
produce significant bone marrow erythroid vacuolizations in the 5 
premature subjects when this diet was preceded by Diet I (modified cow's 
milk). The number of erythroid precursors with vacuolizations and the 
number of vacuoles in each immature red cell varied from subject to 
subject, with the bone marrows of SP2 and F02 being the least involved 
(Fig. 8). The Wright -Giemsa stained bone marrow specimens revealed 
similar patterns regardless of the site from which the marrow was 
aspirated. In general, the cellularity of the specimens was considered 

































































































































































































































































































































































































































the presence of vacuolizations in the erythroid elements, most numerous 
in the erythrogones and normoblasts A and less numerous in normoblasts 
B. The vacuoles were cytoplasmic, round, and of variable size and 
number in a given cell. They were never seen in the more mature 
erythroid precursors (normoblasts B) when absent in the erythrogones and 
normoblasts A. The maturation of the erythroid series was always normo- 
blastic; megaloblasts were not seen, and there was no evidence of a 
maturation arrest. Maturation of the myeloid series was also normal 
without maturation arrest, and the megakaryocytes were present in 
normal numbers and appeared to be making platelets. Myeloblasts, 
promyelocytes, myelocytes, and metamyelocytes also contained cytoplasmic 
vacuoles. These vacuoles were round and of variable size within a 
cell. In general, they were slightly larger and less numerous in any 
given cell than were the vacuoles in the erythroid precursors. The 
largest vacuoles were noted in the eosinophilic myelocytes and metamye- 
locytes. Vacuoles were not found in the megakaryocytes, reticuloendo- 
thelial cells, and lymphocytes. Free iron was demonstrated in the bone 
marrow by the Prussian Blue stain. Fig. 9 depicts the typical cyto- 
plasmic erythroid vacuolizations produced by feeding Diet III for 2 days 
after. the infant had been receiving Diet I. 
Erythroid vacuolization was not seen when FO and SP received Diet 
II for 2 to 4 days and then Diet III for 2 days. Nor were erythroid 
vacuoles seen in the bone marrow of the 2 full term infants FR and SU 
Fig. 9 55. 
Control 
Deficient ïiiet 




and the older child OB after they had ingested the deficient diet for 
2 to 4 days in various experiments. Definite vacuoles morphologically 
indistinguishable from those in Fig. 9 did appear in the cytoplasm of 
the myeloblasts, myelocytes, and metamyelocytes under these experimental 
conditions in FO, SP, OB, and FR. 
Bone marrow and blood examinations were also carried out after 
only 24 hours on Diet III following Diet I in infant U.A. The findings 
were the same as seen in all 5 premature infants after 48 hours of 
deficiency although they were less marked. Two days of Diet II following 
the deficient diet sufficed to revert the bone marrow to normal morpho- 
locic appearance in all cases although the serum phenylalanine concen- 
trations had not fully returned to control values in each instances. 
Three infants (SU, RU, FR) were fed Diet II for 6 to 14 days and 
then Diet III for 4 to 5 days in order to show more clearly the 
effect of the ingested load of amino acids upon serum and urinary 
concentrations and differentiate it from the dietary deficiency of 
phenylalanine per se. Serum and urine concentrations of amino acids 
for these 3 infants -are given in Table V. The increases in amino 
acid concentrations in serum and urine which were found in all 
infants receiving Diet II occurred as expected in these studies. 
When the diets fed these infants were changed from Diet II to Diet 
III, nonsignificant effect on amino acid concentrations other than 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cell progenitors of RU were seen after 5 days of Diet III but not 
after 2 days'in this sequence. SU developed no marrow changes, 
and FR developed vacuoles in only the myeloid cells. 
Three infants (SP, HU, JO) were given supplemental amounts of 
150 mg, lg, and 1 g of alanine per day respectively and two infants 
(FO, JO) 150 mg and 0.5 g of valine per day during control periods 
of Diets I or II and during periods on the deficient diet to deter- 
mine whether there.was any toxic effect on bone marrow. No vacuoles 
or other toxic effects of the amino acids were demonstrable nor were 
any seen in RU's bone marrow when L- methionine, 200 mg per day, was 
added for three days to Diet I. Serum levels of the administered 
amino acid were increased after these supplements. 
No significant changes in bone marrow specimens or amino acid 
concentrations in infant HY were demonstrated following a 24 -hour 
period in which he ingested only carbohydrate and water. 
CO ENT: The striking features of this study were the rapidity 
with which the premature infants showed evidence of phenylalanine 
deficiency with depression of serum phenylalanine concentration and 
the rapid development of vacuoles in the cytoplasm of the red cell 
precursors in the bone marrow. The bone marrow lesions were as rapidly 
reversed when phenylalanine was added to the diet. 
59. 
In none of these infants have anaemia, change in circulating 
reticulocytes, or untoward symptoms been seen in the short periods 
in which they received the deficient diet nor in an observation 
period of several months thereafter. 
The severity of the phenylalanine deficiency may have been 
accentuated by the increased intake of other amino acids in the 
deficient diet. A load effect was clearly demonstrated with marked 
increase of serum concentrations of methionine, valine, alanine, and 
lysine and lesser increases of other amino acids when infants inges- 
ted either Diet II or III. This was accompanied by increased 
urinary excretion of these amino acids. It is likely that much of 
the excess amino acid in the urine was of the D -form (Schendel et al, 
1959) but this was not determined. The effect of the increased 
intake of amino acids was sufficient to obscure any possible effect 
of phenylalanine deficiency per se on amino acid concentrations. 
Supplemental ingestion of methionine, alanine and valine produced no 
apparent bone marrow or haematologic effects. Therefore, it is 
unlikely that the bone marrow changes noted can reasonably be attri- 
buted to other than phenylalanine deficiency. 
Premature infants, RU, FO, and SP did not develop cytoplasmic 
vacuoles in cells of the erythroid series after 48 hours of the 
deficient diet when the preceding control diet had been Diet II. RU 
continued to be fed Diet III for another 3 days and then had eryth- 
60. 
roid vacuoles in his bone marrow. This inhibition of vacuole formation 
may have been the result of greater phenylalanine intake with Diet 
II whan with Diet I (125 mg per kg per day vs. 90 mg per kg per day). 
If this were so, it -would suggest that cow's molk modified as in 
Diet I contains less than optimal quantities of phenylalanine for 
the needs of premature infants. On the other hand, the greater 
tyrosine content of Diet II might have made the infants more resis- 
tant to phenylalanine deficiency since an excess of tyrosine can 
reduce the daily requirements for phenylalanine of the older indi- 
vidual. The age of these premature infants prevents acceptance of 
this speculation although the increased tyrosine intake might have 
been important in the resistance of the full term and older infants 
to the effects of the phenylalanine- deficient diet. 
All subjects except SU developed vacuoles in their white cell 
precursors after 48 hours of the deficient diet. The presence of 
myeloid vacuoles in the absence of erythroid vacuoles may reflect 
the more rapid rate of turnover of white cells. On the other hand, 
vacuolization of mature granulocytes is seen in a variety of bacte- 
rial infections (Ponder and Ponder, 1942). Some support for the 
hypothesis that longer periods of deficiency are required for develop- 
ment of erythroid vacuoles is derived from the observation that 
erythroid vacuoles never were seen in these studies in the absence 
of myeloid vacuoles. 
61. 
The bone marrow changes may be reversed before the serum 
phenylalanine' concentrations are fully returned to control values 
when the infants are given phenylalanine supplements. 
Although the concentrations of amino acids tended to be 
greater when serum rather than plasma was used, the changes noted 
were comparable. This was not unexpected since it has previously 
been reported that the concentration of total amino acids is greater 
in serum than in the comparable plasma (lacFayden, 1942). This 
same relationship has been found to hold for individual amino acids 
(Stein and Moore, 1954). 
62. 
Study 2: 
a) Effect of Chloramphenicol on Bone Marrow and Amino Acids in 
Infants. 
b) Effect of Ingestion of Phenylalanine on the Toxic Action of 
Chloramphenicol on Bone Marrow. 
The major toxic effect of chloramphenicol is the production 
of bone marrow arrest and aplastic anaemia. Early in the development 
of chloramphenicol toxicity, vacuoles appear in the erythroíd and 
myeloid precursors in the bone marrow (Saidi and Wallerstein, 1960; 
Saidi et al, 1961; Rosenbach et al, 1960; and McCurdy, 1961). The 
relation of these early, reversible lesions to later, more serious 
bone marrow depression is unknown. Similar cytoplasmic vacuoles in 
the erythrogones have been reported in erythraemic myelosis (Di 
Guglielmo, 1962), acute alcoholism (McCurdy et al, 1962), kwashiorkor 
(Foy and Kondi, 1964), and in an infant with phenylketonuria receiving 
a phenylalanine deficient diet (Sherman et ai, 1964). The lesions 
in the infant receiving this diet were reversed by the addition 
of phenylalanine. An attempt is made to study the effect of the 
administration of phenylalanine upon the vacuolization of the eryth- 
rogones produced by chloramphenicol. The study was also designed 
to correlate the amino acid content of blood and amino acid excretion 
in the urine with the bone marrow changes. 
SUBJECTS: Chloramphenicol was administered to 9 children for 
treatment of a variety of infections. These included shigellosis 
63. 
with diarrhea, septicaemia and urinary infection due to Escherichia 
colí, meningitis due to Haemophilus influenzae Type B and salmonella 
in a patient with sickle -cell disease. The physician responsible 
for the patients' care decided to institute and to discontinue the 
antibacterial therapy. Chloramphenicol was administered in doses of 
50 to 100 mg. per kilogram of body weight per day parenterally or by 
mouth. Patients ranged in age from a newborn infant, three days old, 
to an eight year old girl and in size from 1.7 to 21.0 kg. Table VI 
lists the illnesses, ages, weights and sex. During the last six 
days of chloramphenicol treatment, B.A. ingested, in addition to his 
diet, 1 gm. of L- alanine per day for two days and then 100 gm. of 
L- phenylalanine per kilogram of body weight for the last four days. 
Similarly, the diets of B.R., S.I. and L.O. were supplemented with 
the same dose of phenylalanine for the last two, three and six days 
of chloramphenicol treatment respectively. 
The newborn infants were given a diet consisting solely of a 
proprietary milk mixture modified by the manufacturer to simulate 
human milk.* The older infants and children took a mixed diet well 
except for S.I., who was sick enough that this intake was poor for 
the first four days of treatment, and B.A., the patient with meningitis 
due to H. influenzae Type B, who was maintained on intravenously ad- 
ministered fluids for the first week of therapy and thereafter received 
only cow's milk by mouth. 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































METHODS: Bone marrow specimens were obtained from the iliac 
crests or tibias before the beginning of chloramphenicol therapy, 
after two or three days and six to nine days of treatment with chloram- 
phenicol and at intervals of two or three days thereafter. Bone 
marrowswere examined after staining with Wright- Giemsa medium. An 
independent assessment was also made by a haematologist (J.D.S.) 
who was unaware of the patient's disease and of the treatment adminis- 
tered. At the time of bone marrow aspiration, venous blood was 
obtained for measurements of amino acid concentrations in serum or 
heparinized plasma. The Technicon Auto -Amino Acid- Analyzer modifi- 
cation of the method of Moore and Stein was employed. Measurements 
of proline, glycine, alanine, valine, methionine, isoleucine, leucine, 
tyrosine, phenylalanine, lysine, histidine and arginine were made. 
Twenty -four hour collections of urine were obtained from 3 children 
(B.U., B.R. and T.A.). Total urinary free amino acid excretions 
were determined by ion exchange on Dowex -50 columns by means of the 
ninhydrin end point of Moore and Stein. Identification was carried 
out by two -dimensional paper chromatography with the use of the 
phenol- ammonia -water and the butanol- acetic acid -water systems. 
Aliquots for paper chromatography were adjusted to contain 4 microgm. 
of creatinine as determined by the method of Peters. Estimations of 
quantitative changes of individual amino acids were made from one - 
dimensional chromatography, the size and intensity of the stained 
area being used. Chloramphenicol concentrations in the blood of 4 of 
66. 
the patients were measured by Dr. C. F. Weiss and Dr. C. E. Moyer, 
of Parke, Davis .and Company, Detroit, Michigan. Microhaematocrit 
and reticulocyte determinations were carried out by standard methods. 
RESULTS: All the children recovered from the infections for 
which they were being treated with chloramphenicol. No relation 
between the therapy and slight anaemia that developed in several 
children could be established. In S.I., the patient with sickle - 
cell disease and salmonella osteomyelitis, a hypoplastic crisis 
developed during therapy; the haematocrit fell from 28 to 14 per 
cent, and he was transfused with packed red cells, which returned 
the haematocrit to 27 per cent. At the time of the hypoplastic 
crisis the reticulocyte count was only 1 per cent. Three days 
after the end of therapy, his count rose to 5 per cent, and the bone 
marrow showed erythroid hyperplasia. The reticulocyte counts and 
appearance of smears of peripheral blood in the other patients did 
not alter during the study. 
Table VI. presents the values for amino acid concentrations in 
serum or plasma of the 9 subjects during the course of therapy with 
chloramphenicol. Also given are the times when venous -blood speci- 
mens were obtained and the bone marrow appearance at these times. In 
5 of the patients (B.R., T.A., S.I., B.A. and L.O.) numerous vacuoles 
developed in the erythroid precursors of the bone marrow. l.n R.O., 
vacuoles developed only in rare erythrogones. Numerous vacuoles are 
67. 
occurred in the myeloid precursors of these patients. These changes 
were morphologically identical with those seen in the infants receiving 
a phenylalanine- deficient diet. B.U. and ìM O., in whom erythroid 
vacuoles did not develop, had vacuoles in the myeloid precursors. 
There were no changes in the bone marrow of F.L. after nine days of 
chloramphenicol therapy. The appearance of the bone marrow specimen 
was similar regardless of the site of aspiration. In general, the 
cellularity of the specimens was considered normal except in the 
patient with sickle - cell disease mentioned above. The maturation of 
the erythroid series in the other patients was always normoblastic, 
without evidence of any arrest. The maturation of the myeloid series 
was normal in all specimens without maturation arrest. Megakaryocytes 
were present in normal numbers, and platelets production appeared 
normal. 
The most striking findings were the presence of vacuolizations 
in the erythroid elements. The vacuoles were most numerous in eryth- 
rogones and normoblasts A and less numerous in normoblasts B. The 
vacuoles were cytoplasmic, round and of variable size. The numbers 
of vacuoles in each immature red cell varied from subject to subject. 
They were never seen in the more mature normoblasts B when absent in 
the erythrogones and normoblasts A. 
Myeloblasts, promyelocytes, myelocytes and metamyelocytes con- 
tained similar cytoplasmic vacuoles. They were round and of varying 
size and, in general, were slightly less numerous in a given cell 
68. 
than the vacuoles in the erythroid precursors. Vacuoles were not 
found in megakarÿocytes, reticuloendothelial cells and lymphocytes. 
The administration of chloramphenicol was discontinued by the 
physicians guiding the clinical therapy in B.U., R.O., íM O., F.L. 
and T.A. after seven to nine days of treatment. Chloramphenicol admi- 
nistration was continued for six more days from the time of the 
appearance of the vacuoles in B.A. and L.O., two more days in B.R. 
and three more days in S.I. These four patients were the sickest of 
the group. B.A. had meningitis, and S.I., osteomyelitis, and B.R. 
and L.O. were newborn infants with septicemia due to Esch. coli. The 
bone marrow changes in B.A. were not affected by the administration 
of alanine for two days, but the administration of phenylalanine was 
associated with a return of the bone marrow to normal in B.R., L.O. 
and B.A. and a reversal of the changes in S.I. to the point that only 
rare erythrogones were seen to contain a few very small vacuoles. 
Fig. 10 demonstrates photomicrographs of bone marrow specimens obtained 
from B.R. before chloramphenicol administration, after eight days of 
chloramphenicol treatment and after two days of phenylalanine adminis- 
tration in addition to chloramphenicol. The typical cytoplasmic 
erythroid vacuoles are readily seen after eight days of chloramphenicol 
administration but are no longer present after two days of additional 
chloramphenicol therapy coupled with the ingestion of L- phenylalanine, 





Chloramphenicol plus Phenylalanine 
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After seven and eight days of chloramphenicol therapy, the bone 
marrow specimens from L.O. and B.A., respectively, revealed similar 
vacuoles in the cytoplasm of both the red -cell and white -cell series. 
After four more days (B.A.) and six more days (L.0.) of chloramphenicol 
therapy combined with the ingestion of 100 mg. of phenylalanine per 
kilogram per day, the bone marrow specimens were completely normal. 
A specimen (from B.A.) obtained two days after the beginning of 
phenylalanine supplementation still contained cytoplasmic vacuoles of 
the erythrogones, but the myeloid vacuolization was no longer present. 
L.O. showed rare erythroid vacuoles after four days of phenylalanine 
with no myeloid vacuoles. Only a few erythrogones contained cytoplasmic 
vacuoles after the addition of 100 mg. of L- phenylalanine per kilo- 
gram per day to the diet of S.I. even though the administration of 
chloramphenicol was continued. In addition, the vacuoles still 
present not only were fewer in number per involved cell but also were 
much smaller in size. At this time, no vacuoles were found in the 
myeloid series. 
Table VI shows that the measured serum and plasma amino acid con- 
centrations increased when chloramphenicol was administered. This 
increase was generalized, but only alanine and lysine concentrations 
rose significantly. The increase in circulating amino acid concen- 
trations was greatest in the youngest infants (B.R., M.O., B.U., L.O. 
and .O.). When the bone marrow changes improved after supplementation 
of the diet with phenylalanine the concentration of most of the amino 
71. 
acids decreased or remained the same whereas alanine concentrations 
continued to increase significantly. 
Urinary amino acid excretion increased rapidly with chloramphe- 
nicol therapy and then tended to reach a plateau paralleling serum or 
plasma levels. This increased excretion was made up in large part of 
alanine,glycine, proline and histidine. A perceptible increase of 
phenylalanine excretion was also associated with chloramphenicol 
administration. Urinary amino acids were examined in only 1 patient 
treated with phenylalanine after the bone Marrow lesion had been demon- 
strated. In this case, the administration of phenylalanine did not 
seem to make any difference in the urinary pattern of total free amino 
acid or individual amino acid excretion. 
Chloramphenicol concentrations in serum varied widely from patient 
to patient and to a lesser extent from time to time in the same patient. 
There was no correlation between the average or individual concentra- 
tions of chloramphenicol and the morphologic appearance of the bone 
marrow. 
COMMENT: It seems reasonable to assume that the vacuoles seen 
in the erythroid precursors of the bone marrow were indeed a toxic mani- 
festation of chloramphenicol since the other conditions in which such 
vacuolization has been observed - erythremic myelosis, acute alcoholism, 
dietary phenylalanine deficiency and kwashiorkor - need not be consi- 
dered in these patients. It is possible that the vacuoles seen in the 
72. 
cytoplasm of myeloblasts, promyelocytes, myelocytes and metamyelocytes 
were also produced by chloramphenicol. However, vacuoles may be 
seen in circulating mature granulocytes in infections. The corre- 
lation in time of appearance of the vacuoles in the myeloid series 
with that of erythroid vacuoles suggests similar pathogeneses. The 
myeloid vacuoles appeared sooner and, at times, disappeared more 
rapidly ou recovery than the erythroid vacuoles, as might be expected 
from the more rapid rate of myeloid -cell turnover. In patients with 
phenylalanine deficiency the erythroid vacuoles were never seen in 
the absence of myeloid vacuoles. 
The changes in circulating free amino acid concentrations suggest 
a block in the utilization of amino acids. Increased urinary excre- 
tion of these amino acids rules out the possibility that the eleva- 
tions in serum or plasma concentrations were due to renal dysfunction 
produced by chloramphenicol. The greatest increases in circulating 
free amino acids were noted in the youngest children. 
73. 
Study 3: Chloramphenicol and L- phenylalanine Therapy in Experi- 
mental Klebsiella Pneumoniae Infection in Mice. 
The ingestion of L- phenylalanine has been shown to reverse 
one of the early toxic effects of chloramphenicol on human bone 
marrow, namely, the cytoplasmic vacuolization of erythrogones. The . 
relationship of these vacuoles to the aplastic anaemia associated 
with chloramphenicol treatment is not clear. Before investigating 
the possibility that prophylactic administration of phenylalanine 
might prevent the later more serious toxic effects of chloramphe- 
nicol, it is necessary to evaluate the effect of administration of 
the amino acid upon the antibacterial efficacy of chloramphenicol. 
The need for the study was also suggested by the possibility 
that the cytotoxic effect of chloramphenicol in clinical situations 
and the antibiotic activity of the drug might involve a common 
mechanism. In addition, Woolley (1950) reported that phenylalanine 
inhibits the antibacterial action of chloramphenicol in vitro. 
MATERIALS AND METHODS: The following materials in varying 
combinations were injected into Swiss White male mice (25 + 2 gm 
initial weight) in each test. A strain of Klebsiella pneumoniae 
isolated from the blood culture of a patient was used throughout. 
The organism was maintained and. diluted in brain- heart infusion broth. 
Mice were infected intraperitoneally with 0.5 ml of an overnight 
74. 
culture diluted 10 -2 in all but two experiments which used 10 -4 
dilutions. An overnight culture resulted in approximately 1010 
organisms /ml with an 
LD50 
of 10 -3'6. The minimum inhibiting concen- 
tration of chloramphenicol for the infecting strain was 6.26/m1. 
L- phenylalanine was injected subcutaneously in a volume of 
0.4 ml suspended in 0.89 per cent sodium chloride acidified to pH 4 
with 1 N HC1. Acidified saline, 0.4 ml, was used as a control solution. 
Chloramphenicol succinate was given subcutaneously in a volume 
of 0.2 ml at a site distant to that employed for the phenylalanine. 
Nice under light ether anaesthesia were given the intraperi- 
toneal injection of organisms followed in rapid sequence by the sub- 
cutaneous chloramphenicol and phenylalanine or control solution in 
all but one test. In the latter, the phenylalanine or control solution 
was injected four hours before the other injections. Cages were 
inspected twice daily at which time the numbers of dead mice were 
recorded. The animals were observed for ten days, but the final 
mortality was reached in all experiments by 72 hours, most deaths 
occurring in the first 36 hours. In two experiments, the dose of 
chloramphenicol was varied between 10 and 70 mg /kg; in all others, 
the dose was 25 to 40 mg /kg. 
RESULTS: All the infected animals that did not receive chloram- 
phenicol died whether or not they received phenylalanine in doses 
75. 
from 50 to 400 mg /kg, All non -infected animals given phenylalanine 
or saline with or without chloramphenicol survived. 
Fig. 11 demonstrates the effect on mortality of phenylalanine 
in two dose ranges, 50 -100 mg /kg and 300 -400 mg /kg, when the dose 
of chloramphenicol is between 25 -50 mg /kg. There is a decrease in 
mortality at the lower dose which is not statistically significant. 
At the higher range, there is a significant increase in mortality. 
In other words, the higher dose of phenylalanine is detrimental 
to the antibiotic efficacy of chloramphenicol. 
Table VII presents the data from these experiments. The results 
include those of the experiments with pre- loading of phenylalanine 
as there was no difference in host response between this group and 
all the others where the animals were given phenylalanine simultaneously 
with the infecting organisms and chloramphenicol. Fig. 12 represents 
the same results graphically. The results are grouped in the table 
both by dose of chloramphenicol and by the ratio of phenylalanine to 
chloramphenicol dosage. The ratio is given both as mg /mg and 
rmiol /mmol. The significance of the differences was calculated by the 
fourfold table, and the values of both x2 and p are given. 
It may be seen that the addition of phenylalanine in doses 
approximately equimolar to the doses of chloramphenicol (0.6 - 1.3 
mmol /mmol) reduced mortality significantly from that of the animals 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Doses of phenylalanine which on a molar bases were 2 to 5 
times those of chloramphenicol had no significant effect on overall 
mortality. When only those animals which received 25 to 40 mg /kg 
of chloramphenicol are considered, however, these doses of phenyla- 
lanine had an adverse effect which was statistically significant 
o 0 5 ) . 
Larger amounts of phenylalanine (molar ratio to chloramphenicol 
of 8- 20/1.) markedly increased mortality. 
Thus, equimolar doses of phenylalanine augmented the beneficial 
effects of chloramphenicol while 8 to 20 times as much phenylalanine 
inhibited the antibiotic effect. Intermediate doses of phenylalanine 
(2 -5 times those of chloramphenicol) probably inhibited antibiotic 
effect. 
COMMENT: The interaction of phenylalanine and chloramphenicol 
in relation to mammalian protein synthesis and bacterial growth is 
one of great interest. Its significance in therapeutic situations 
remains to be proven. Woolley (1950) proposed that the antibiotic 
could be regarded as a metabolic analogue of phenylalanine. Jardetsky 
(1962, 1964) and others have shown that chloramphenicol will block 
the incorporation of amino acids into protein at the ribosome and it 
may be that phenylalanine counteracts the chloramphenicol affect at 
this level. Whatever the final mechanism, the present study suggests 
that parenteral L- phenylalanine given in a dose equivalent to that 
30. 
of the chloramphenicol will not inhibit the drug's antibacterial 
activity in the experimentally infected mouse. Indeed, there is a 
potentiation of the host resistance to Klebsiella infection. This 
is not a direct effect of the amino acid since phenylalanine by it- 
self had no demonstrable antibiotic activity. A preferential uptake 
of phenylalanine by the host cell might block the site of activity 
of chloramphenicol on the host cell and yet allow a more effective 
antibacterial concentration of chloramphenicol outside the host cells. 
Another possible explanation is that this dose of phenylalanine might 
prevent the inhibitory effect which chloramphenicol has on some 
protein dependent body defence mechanisms such as antibody formation. 
This possibility will be considered later in the thesis. 
The inhibition of chloramphenicol's effectiveness by the larger 
doses of phenylalanine is consistent with the in vitro studies of 
Woolley. L- phenylalanine is known to directly inhibit antibody response. 
(Ryan, 1965), so this may be another factor in the diminished host 
response to. infection. 
The relevancy of these findings to infections with other 
organisms or to human infections remains to be established. In the 
previous study (2b), phenylalanine was given to patients only after 
three to eight days of effective chloramphenicol therapy. The results 
presented, however, suggest that further investigation of the combined 
use of the phenylalanine and chloramphenicol in clinical situations 
would be both worthwhile and appropriate. 
81. 
Study 4: Effect of Phenylalanine Deficient Diet and Chloramphenicol 
on the Bone- marrow of young Rats. 
In an attempt to identify the nature of the cytoplasmic 
vacuoles, a variety of staining techniques for fat, tyrosine, deso- 
xyribonucleic acid and ribonucleic acid were tried on the bone 
marrow slides from phenylalanine deficient infants and infants 
treated with chloramphenicol. The vacuoles failed to take any of 
the stains tried. It was felt that the vacuoles might contain 
biosynthetic precursors of protein and nucleoprotein so an attempt 
was made to introduce tritiated amino acids and nucleic acid and 
see if these substances would localise in the vacuoles. 
METHODS: Male and female rats of the Sprague -Dawley strain, 
1 month old and weighing 70 G + 5 G, were used. The low phenylala- 
nine diet employed was Cymogram*, which contains only 10 mg. 
phenylalanine per 100 G of preparation. The phenylalanine require- 
ment of the rat is only 10 mg. /kg. body weight /day. A control diet 
was the same casein hydrolysate with added L-pheuylalanine. Rats 
were force -fed by plastic gastric tube twice daily and had free 
access to water. 
* Cymogram - Allen and Hanburys, Ltd., London. 
82. 
Chloramphenicol was administered as chloromycetin succinate 
by subcutaneous injection. at a dose equivalent to 400 mg. /kg. body 
weight /day. Control animals were injected with a like volume of 
N saline. Rats were weighed daily and at the eighth day when the 
experiment was ended. 
Twenty -four hours before the animals were sacrificed, tritiated 
alanine, phenylalanine or uridine was injected by the tail vein. 
In all experiments, several groups of animals, each of the 
same sex, age and weight, were used. 
DIETS: Diet A was the casein- hydrolysate low phenylalanine diet. 
Diet B the same with a complement of L- phenylalanine. 
The animals were sacrificed at the eighth day, having been 
anaesthetised with intraperitoneal pentobarbitone, then elpnguinated 
by collecting blood from the abdominal aorta. Bone -marrow smears 
were obtained from the split femora. 
RESULTS: There was a very high mortality from the force -feeding 
of the deficient diet and the groups of animals were combined so 
that the results are given for 15 survivers in each group in Table 
VIII. Haemoglobin, haematocrit and reticulocyte values showed no 
significant differences in the 4 groups. Chloramphenicol blood con- 















































































































































































































































































Animal on the Left was force -fed a phenylalanine 
deficient diet (Diet A) for 8 days. 
Control animal on the Right was a litter -mate, 
force -fed an isocaloric but nutritionally 
complete diet (Diet B) for 8 days. 
85. 
hkq 
It can be seen (Table VIII) that there was aÀfnortality when 
Diet A was fed alone and was somewhat lower when combined with 
chloramphenicol. Fig. 13 compares the appearance of an animal from 
Diet A group with one from Diet B. It shows the runted appearance, 
poor hair and general wasting. 
Unfortunately, vacuoles were not produced in the cytoplasm 
of the red cell precursors in any of the marrows examined. Retí- 
culoendothelial cells in both the group A diet and group A diet with 
chloramphenicol did show vacuoles. No particular localisation of 
the radioactive amino -acids or uridine could be determined and there 
was no localisation to the few vacuoles present in some cells of the 
reticuloendothelial system. 
COMMENT: The high mortality of the force -fed deficient diet 
group is in keeping with the findings of Sídransky and Verney (1964). 
Failure to produce vacuoles with chloramphenicol in the rat is 
probably the result of the very rapid excretion of this drug by the 
rat. The choice of animal for this experiment was unfortunate. 
Monkeys of the Rhesus type have produced vacuoles following chloram- 
phenicol therapy and would probably be the animal of choice for this 
experiment. 
ú6. 
Study 5: Management and Progress of Two Phenylketonuric Infants 
Diagnosed Early. 
The application of the Guthrie (1961) screening test in the 
neonatal period has greatly facilitated the early diagnosis of 
phenylketonuria. Two such infants, where the diagnosis was -made 
by this technique, had the diagnosis confirmed at the eighteenth 
and twenty -third days of life respectively. The following is a 
description of their response to a restricted dietary intake of 
phenylalanine. 
SUBJECTS: J.M. was diagnosed as having phenylketonuria at 
eighteen days of age. He is a white male infant born normally at 
term with a birth weight of 2.3 kg. his history and family history 
are given in Appendix I. 
B.G. was diagnosed as having phenylketonuria at twenty -three 
days of age. He .is a white male infant born prematurely at seven 
months gestation with a birth weight of 1.75 kg. His history and 
family history are given in Appendix I. 
METHODS: Th6 initial dietary management with a low phenylala- 
nine diet (Lofenalac - Head Johnson) was that generally recommended 
(Hsia et al, 1955). Sufficient of this formula for caloric and 
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fluid requirements was given and the phenylalanine intake adjusted 
to 20 mg/kg body weight per day. 
Blood amino acid concentrations were determined on 0.2 ml. 
samples of capillary whole blood by column chromatography. See 
Appendix II for a full description of the method. 
Where low blood concentrations of phenylalanine indicated 
that an increase of dietary phenylalanine was required, this was 
achieved by adding small increments of pure L- phenylalanine to the 
Lofenalac diet. When the required amount of additional L- phenyla- 
lanine, which maintained a blood concentration of 1 -2 mg per 100 ml 
had been determined, the volume of whole cow's milk which would 
supply this amount of amino acid was estimated and the diet so 
complimented. 
Bone marrow was aspirated from the iliac crests and tibias 
and stained with Wright -Giemsa stain. These specimens were also 
examined by a haematologist (J.D.S.), an independent assessor,who 
was unaware of the patient's clinical state. 
Microhaematocrit and reticulocyte counts were performed by 
standard methods at regular intervals throughout the periods of study. 
J. í. - Management and Progress: The blood phenylalanine 
concentration at 18 days of life was 26.7 mg per 100 ml and the 
UV. 
decision to start therapy was made after full assessment. A low 
phenylalanine diet which allowed a phenylalanine intake of 20 mg /kg/ 
day was commenced. After two days on this regimen, the blood 
phenylalanine was 9.2 mg /l00 ml, and after five days, values of less 
than 0.1 mg /100 ml were reached. At this point in time, vacuolization 
of the cytoplasm of the red cell precursors in the bone marrow 
became apparent (Fig. 14). These changes persisted while blood 
levels of phenylalanine were below 0.1 mg /100 ml (6- 94moles per 
litre). As with the normal infants on this diet described in Study 1, 
there were elevated blood levels of alanine, lysine, valine and 
methionine. while the phenylalanine concentration remained at a 
low level, .L-alanine, 1 G per day, was fed in addition to the low 
phenylalanine diet for four days. The blood levels of alanine 
increased as a result but the phenylalanine concentration remained 
low and the marrow vacuoles persisted. Lysine, 400 mg, per day, 
' Valine, 400 mg /day and Methionine, 200 mg /day, fed each in turn for 
3 days similarly failed to eradicate the vacuoles present in the 
red and white cell precursors. 
Increments of pure L-- phenylalanine were gradually added to the 
diet and it finally required a phenylalanine intake of 50 mg /kg per 
day to maintain the blood phenylalanine concentration between 1 -2 mg' 
per 100 ml. at which time the bone marrow reverted to normal and 
there was a marked reticulocyte response. The quantity of whole 




calculated and this volume added to the low phenylalanine diet in 
place of the pure L- phenylalanine. 
The weight chart, dietary intake of phenylalanine and capillary 
whole blood phenylalanine concentrations for the first year of life 
are shown in Fig. 15. It can be seen that a dietary intake of 
40 -50 mg. phenylalanine /kg per day is necessary to maintain an 
adequate blood level of the amino acid. 
Haemoglobin. values were slow to rise in spite of additional 
iron, riboflavine, vitamin B12, folic acid, vitamin C and vitamin L 
supplements. At two months of age, his haemoglobin was 7.0 G /100 ml. 
blood. When the additional dietary phenylalanine was introduced, 
the marrow vacuoles resolved and within a period of 19 days, the 
haemoglobin had risen to 8.4 G /100 ml. There is little doubt that 
during the period from the twenty -third day of life until the sixty - 
fourth day, the blood phenylalanine concentrations were somewhat 
below the optimum value. 
Between the tenth and eleventh month of life, the mother 
relaxed the diet and it proved impossible to estimate the intake of 
phenylalanine. When strict dietary control was re- introduced, blood 
phenylalanine concentrations quickly returned to the normal range. 
Blood tyrosine and other amino acid concentrations were never outside 
the accepted range of normal. 


















































































































Levelopmental Schedules gave a developmental level of approximately 
20 weeks and the electroencephalograph at this time was normal. 
A repeat assessment at 12 months of age showed a developmental 
level of about 10 months while his weight was approaching the 50th 
percentile for his age and the haemoglobin was 11.5 G /100 ml. The 
electroencephalograph was again normal. 
B.G. - Management and Progress: At twenty -three days of age, 
the patient weighed 1927 G and had a blood phenylalanine concentration 
of 42 mg. per 100 ml. He, at this time, started a low phenylalanine 
(Lofenalac) diet which allowed a daily intake of 50 mg. phenylala- 
nine per day. For three weeks, there was a reasonable weight gain 
but then his weight gain slowed. The skin rash which had been 
present from about the 6th day of life became suddenly much worse 
with intense erythema and desquamation. He became extremely 
irritable and increasingly pale. His haemoglobin was 8.2 G with a 
haematocrit of 28% and the red cells showed hypochromia and slightly 
macrocytosis. The white blood cell count was 10,500 per cu. nun. 
with a normal differential and normal platelet count. The total 
red cell count was 3.2 million per cu. mm. and the reticulocyte 
count was 2 %. A negative Coombs test and less than 1 mg./100 ml. 
bilirubin concentration, a normal serum folic acid (8.1 m/e4(G /ml.) 
and serum vitamin B 1 (440G /m1.) were found at this time. The 
total serum protein was 5.0 G /100 ml. with albumin 45.3 %, alpial 
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globulin 9.7 %, alpha2 globulin 8.3 %, beta globulin 23.6% and gamma 
globulin 12.5 %. Serum electrophoresis and immunoelectrophoresis 
were normal, serum iron was 50 /j0/l00 ml. and serum unsaturated 
iron -binding capacity was 300 G/100 ml. 
The serum phenylalanine concentration at this time was less 
than 0.1 mg % and a bone marrow smear showed that the red cell 
precursors had marked vacuolization of their cytoplasm. Occasional 
myeloid cells, reticuloendothelial cells and plasma cells, as well 
as megakaryocytes,contained vacuoles. The maturation of the 
erythroid series was normoblastic; megaloblasts were not seen, and 
there was a mild increase in erythrogones and normoblasts A and B 
suggestive of a slight maturation arrest in this series. The matura- 
tion of the myeloid series was normal without maturation arrest 
and the megakaryocytes were present in normal numbers and appeared 
to be making platelets. 
Twenty -five ml. of packed red cells was.given and 150 mg. 
phenylalanine /day was added to the diet. The infant showed a sus- 
tained weight gain from 2233 G to 2550 G in the following 9 days; 
the skin rash cleared and the infant was much less irritable. He 
was discharged home at this point with a haemoglobin of 9.4 G /100 ml. 
and a normal bone marrow.is mother put him on to a whole milk 
diet and when he returned after one week, his blood phenylalanine 
was 60 mg. /100 ml. Strict dietary control was re- instituted with 
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a daily intake of phenylalanine of 200 mg. Bone- marrow vacuoles 
were again apparent after 5 days but resolved when the intake of 
phenylalanine was increased to 380 mg. /day. It was found that 
150 mg. /kg /day phenylalanine maintained a blood level of 1 -2 mg /per 
100 ml. and a normal bone -marrow. 
The subsequent control of dietary phenylalanine was managed 
by frequent estimations of blood phenylalanine concentrations. At 
six months of age, 100 mg /kg /day, and at 12 months, 50 mg /kg /day 
of phenylalanine was the required dietary intake to maintain a 
normal blood phenylalanine concentration. 
At 16 months, he weighed 8.0.kg. (50th percentile for 7 months), 
his length was 70 cm. (50th percentile for 9 months)with a head 
circumference. of 46 cm. (50th percentile for 9 months). His 
haemoglobin was 11 G per 100 mi. with a haematocrit of 32%. 
A psychological evaluation at six months of age,.using Gesell 
Developmental Schedules, gave a developmental level of approximately 
15 weeks and the BEG at this time was normal. The repeat assess- 
ment at 12 months showed a developmental level of about 28 weeks 
and when examined at 16 months of age, he had reached a 50 week 
developmental stage. Again, the electroencephalographs were normal. 
C01,ENT: These two cases illustrate well the difficulties 
involved in controlling the dietary intake of phenylalanine. The 
95. 
red cell precursor vacuoles appear directly related to low blood 
phenylalanine concentrations, as these changes could not be reversed 
by increased dietary intake of alanine, valine, lysine or methionine 
in J.M. They did resolve promptly when the phenylalanine intake 
was increased and blood phenylalanine concentrations approached 
normality. The anaemia similarly appears to be a direct consequence 
of the phenylalanine deficiency and responded dramatically to the 
increased dietary intake of phenylalanine. 
The quantities of phenylalanine required by these infants is 
much in excess of that generally recommended. 
96. 
Study 6: Folinic Acid - Its Effect on the Phenylalanine Tolerance 
Test in the Phenylketonuric Child. 
The deficiency of the enzyme phenylalanine hydroxylase in 
the infant with phenylketonuria may not be absolute. Udenfriend 
(1953) found that some tyrosine was manufactured from C14 labelled 
phenylalanine fed to phenylketonuric patients. Knox (1958) sugges- 
ted that the small amount of tyrosine formed may be attributed to 
other unknown reactions or to residual activity of the genetically 
distorted enzyme protein. Direct assay of phenylálanine hydroxy- 
lase in the liver of seven older phenylketonuric patients, however, 
failed to show any enzyme activity. 
Jacobson (1964) suggested that if there were any enzyme 
activity in the young infants with phenylketonuria, it might be 
possible to enhance this activity by supplying increased amounts 
of the pteridine cofactor described by Kaufman (1958), Fig. 16. 
If this proved effective, then optimum dietary control of the 
infant might be more readily achieved. 
SUBJECTS: Four children with phenylketonuria were studied. 
B.G. and T.G. were brother and sister, J.M. and C.B. were not related 
to each other or to B.G. Case histories are described in Appendix I 

































































































































































































































































































































METHODS: The four subjects were maintained on their prescribed 
diet with the phenylalanine intake indicated in Table IX. Capillary 
whole blood was obtained for fasting blood amino acid content and 
again at 4, 3, 12, 16 and 24 hours after ingestion of 100 mg /kg of 
L- phenylalanine. The test was repeated after 2 -3 days interval 
when 24 mg. folinic acid (given as 60 mg. Leucovorin) was injected 
subcutaneously before the load of phenylalanine was given. B.G. was 
given his tolerance test with folinic acid 4 days before his control 
phenylalanine tolerance test. 
Free amino acids in whole blood were measured on 0.2 ml. of 
sample by the Technicon Micro- Column Amino Acid Analyzer adaptation 
of the technique of Spackman, Stein and iSoore 0_958). By this 
technique, there are differences between whole blood and plasma 
levels of a number of amino acids. Tyrosine and Phenylalanine con- 
centration in the capillary whole blood samples and capillary 
plasma samples withdrawn at the same time were, however, virtually 
identical. (See Appendix II for a fuller description of the method). 
RESULTS: The patients tolerated the tests well and showed 
no change in their general behaviour. Blood phenylalanine and tyrosine 
concentrations are recorded in Tables -VIII, and the phenylalanine 
tolerance curves in Figs. 17 -20. 
There is no obvious pattern of change in blood tyrosine after 
a phenylalanine load in any of the children whether given folinic 
100. 
TABLÉ X 
J. M. PHENYLALANINE TYROSINE 
/+ moles /litre 
Control Folinic 
/4 moles /litre 
Control Folinic 
0 hr. 77 164 52 63 
4 hr. 1013 325 63 93 
8 hr. 1232 784 142 100 
12 hr. 1630 517 95 83 
16 hr. 713 324 78 127 
24 hr. 103 329 162 13, 
TABLE XI 
B.G. PI- jENYLALANINE TYROSINE 
/* moles /litre 
Control Folinic 
it moles /litre 
Control Folinic 
0 hr. 418 442 51 96 
4 hr. 1170 951 67 96 
8 hr. 2040 914 97 106 
12 hr. 1285 825 57 80 
16 hr. 1099 648 134 
24 hr. 966 380 25 60 
101. 
TABLE XII 





0 hr. 648 300 61 60 
4 hr. 1301 1500 35 27 
6 hr. 1940 1525 83 57 
12 hr. 1332 1469 75 41 
16 i-ir. 946 1074 64 31 
24 hr. 1793 1256 63 31 
TABLE XIII 





0 nr. 1314 966 47 103 
4 hr. 1630 2570 107 93 
s hr. 1268 1681 39 78 
12 hr. 1270 1320 100 55 
16 hr. 1350 1215 60 23 
24 hr. 693 1958 32 90 
PHENYLKETONURIA 
PHENYLALANINE TOLERANCE TEST 
PHENYLKETONURIA 
PHENYLALANINE TOLERANCE TEST 
4 12 
TIME ( hours) 
16 20 24 
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acid or not. The striking feature of the phenylalanine loading test 
is the prolonged elevation of blood phenylalanine which results. 
In the cases studied, it is evident that it requires a period. of 24 
hours after the administration of phenylalanine for blood. concen- 
trations to return to control values. 
The two smaller infants, J.ci. and B.G., show a significant 
reduction in their blood concentrationsof phenylalanine in response 
to the folinic acid. J.M. had previously shown a similar response 
during a trial assessment of the procedure. Folinic acid has no 
obvious effect on the tolerance of the older çhildren, T.G. and C.B., 
to ingested phenylalanine. These latter children had high blood 
concentrations of phenylalanine during the control periods. 
COiThiENTS: The apparent ability of folinic acid to prevent 
the usual high and prolonged elevation of blood phenylalanine in the 
test situation suggests that there is present IL the two infants 
some active system for the metabolism of phenylalanine. It may be 
simply an effect on absorption of phenylalanine from the gut or an 
enhancement of excretion by the renal tubule. Unfortunately, the 
available data cannot decide this. Jacobson's postulate that folinic 
acid might increase the efficiency of reduced quantities of liver 
phenylalanine hydroxylase would require the demonstration of the 
active enzyme in the livers of young phenylketonuric infants. The 
lack of response in the two older children may be due to the relatively 
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smaller dose of folinic acid they received. Alternatively, their 
high blood concentrations of phenylalanine may have produced sub- 
strate inhibition or complete loss of any enzyme activity they might 
at one time have possessed. 
Menkes and Avery (1963) report the effect of folinic acid in 
premature infants unable to metabolise tyrosine and phenylalanine 
normally. They showed a dramatic fall in blood concentrations of 
tyrosine following administration of the folinic acid but do not 
report any corresponding changes in phenylalanine. Their findings 
are consistent with the report of Zannoni et aí,(1963) who found 
that reduced forms of folic acid were required for proper function 
of parahydroxy phenylpyruric acid oxidase, the enzyme deficient in 
Tyrosinosis (Fig. 16, Step 3). The enzyme system which converts 
Tyrosine to DOA also requires a reduced pteridine compound for its 
normal function (Negatsu et al, 1964). Thus, there are at least 
three oxidative enzyme systems involving the aromatic amino acids 
which require a reduced pteridine cofactor (Fig. 16). The improved 
overall efficiency of these liver enzyme systems could explain the 
more efficient handling of a phenylalanine load by the phenylketonuric 
infant and by the premature infant. 
The structure of the naturally- occurring hydroxylation cofactor 
has recently been established as dihydrobioterín (Kaufman, 1963). 
Synthetic tetrahydropteridine compounds more active than folinic acid 
are known but at present are not available in sufficient quantity to 
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test their effect in the phenylketonuric infant. When these compounds 
are available, it would certainly be worthwhile to repeat these 
observations and, if possible, assess their effect on phenylalanine 




The developing foetus and newborn infant requires amino acids 
in specific quantities for the synthesis of structural proteins, 
enzymes and protein hormones, all of which are vital to the growth 
process. Proteins and amino acids involve only one facet of nutri- 
tion and during all phases of growth and development equal atten- 
tion must be given to the carbohydrate, fat, water, mineral and 
vitamin content of the diet. Bearing this in mind, the discussion 
will deal with some aspects of phenylalanine metabolism in relation 
to protein synthesis, haematopoiesis and the growth process. 
The introduction reviews the way in which the concept of 
protein nutrition developed from the recognition of the fact that 
nitrogen containing compounds were essential for tissue and body 
growth. Subsequent discovery of the amino acids and protein structure 
allowed a rational approach to the assessment of diets and their 
relative nutritive values. 
Nutrition and haematopoiesis: The striking findings in Study I 
were the rapidity with which the premature infant showed evidence of 
phenylalanine deficiency, a lowered serum concentration of phenylalanine 
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and the development of vacuoles in the cytoplasm of bone marrow red 
cell precursors. Bone marrow lesions were rapidly reversed when 
phenylalanine was added to the diet. The severity of the phenylalanine 
deficiency may have been accentuated by the increased intake of other 
amino acids in the deficient diet. A load effect from the diet was 
clearly demonstrated with marked increases in serum concentrations 
of methionine, valine, alanine and lysine and lesser increases of 
other amino acids when infants were fed the phenylalanine deficient 
diet or the deficient diet complemented with phenylalanine. This 
was accompanied by increased urinary excretion of these amino acids. 
The increased intake of amino acids was sufficient to obscure any 
possible effect of phenylalanine deficiency der se on amino con- 
centrations. Supplemental ingestion of methionine, alanine and 
valine produced no apparent bone marrow or haematologic change. It 
is unlikely, therefore, that the bone marrow changes noted can be 
attritubed to other than phenylalanine deficiency. 
Three premature infants did not develop marrow changes after 
48 hours of the deficient diet when the preceding control diet had 
been Diet II, which allowed 125 mg /kg /day of phenylalanine. One of 
these infants continued with the deficient diet for a further 3 days 
and did then develop erythroid vacuoles in his bone marrow. The 
failure of these three infants to develop marrow changes as quickly 
as those fed modified cow's milk as the control diet would suggest that 
cow's milk modified as in Diet I (allowing 90 mg /kg /day of phenylalanine) 
contains less than optimal quantities of phenylalanine for the needs 
of some premature infants. On the other hand, the greater tyrosine 
content of Diet II might have made the infants more resistant to 
phenylalanine deficiency since tyrosine can replace about 75% of the 
daily requirements for phenylalanine of the older individual. The age 
of these infants prevents acceptance of this speculation, although 
the increased tyrosine intake might have been important in the resis- 
tance of the full term and older infants to the effects of the phenyl - 
alanine deficient diet. Studies by Holt and Snyderman (1964) on the 
dietary requirements of premature infants were so designed that the 
infants were several weeks old before the requirements could be 
evaluated and again the measurement of the optimum diet was based on 
weight gain, which, as pointed out in the introduction, may not be 
the best method of assessment. Now that a micro technique has been 
evolved (Appendix II) 'for the measurement of blood amino acid concen- 
trations, it would be worthwhile assessing the various diets fed to 
the premature infant on this basis. It is known, for instance, that 
many premature infants are unable to metabolise tyrosine during the 
second week of life (Menkes and Avery, 1963) and that this is asso- 
ciated with later mental retardation if, indeed, it is not the cause. 
Following the reports that mentally retarded infants have been born 
to mothers with phenylketonuria, although the infants themselves do 
not have the disease (Denniston, 1963, and Mabry et al, 1963) and the 
fact that monkeys fed diets with a high phenylalanine content are 
mentally retarded (Waisman, 1965), it is incumbent on paediatricians 
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to ensure a "normal" milieu of amino acids for the rapidly developing 
nervous system of the newborn and premature infant. The effect of 
force feeding an imbalanced amino acid diet to the infant rat is 
clearly seen from the mortality figures and illustrated in Study 4. 
Paediatricians must be sure that they are not replicating this expe- 
riment in a greater or lesser degree when they feed premature infants 
by gastric tube or gastrostomy. 
All the infants in Study 1, except SU, developed vacuoles in 
their white cell precursors after 43 hours of the deficient diet. 
The presence of myeloid vacuoles in the absence of erythroid vacuoles 
may reflect the more rapid rate of turnover of white blood cells. Some 
support for the hypothesis that longer periods of deficiency are 
required for development of erythroid vacuoles is derived from the 
observation that erythroid vacuoles never were seen in the absence 
of myeloid vacuoles. The bone marrow changes may be reversed before 
the serum phenylalanine concentrations are fully returned to control 
values when the infants are given phenylalanine complements. 
Chloramphenicol Toxicity: Toxic reactions to chloramphenicol, 
of main concern, are the production of clinical changes resembling 
shock in the premature and newborn infant and bone marrow depression 
occurring in the infant and older child. Some newborn infants 
receiving chloramphenicol within 46 hours of birth and in doses 
greater than 100 mg /kg /day developed a clinical picture called the 
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"Gray- baby" sundrome (Burns et al, 1959; Sutherland, 1959; Lambdin et 
al, 1960; Lischner et al, 1961). The first evidence of toxicity was 
vomiting followed by refusal to suck and abdominal distention. Res- 
piratory difficulties, flaccidity and an ashen -gray colour followed. 
Deaths occurred in the seriously affected babies from 24 -48 hours 
after the onset of the first symptoms. In the infants studied, 
unusually high blood concentrations of chloramphenicol were found. 
This was probably the result of an inability of the immature liver 
to conjugate the chloramphenicol to the biologically inactive g1ucu- 
ronide. The syndrome has been produced in animals using very high 
doses of the drug (Gruhzít et al, 1949; Kent et al, 1960; Michael 
and 1961). studies quoted were the blood 
or urinary concentrations of amino acids measured. 
Although none of the infants observed in Study 2 developed the 
Cray -baby syndrome, it is of interest that the smaller infants 
developed very high serum concentrations of circulating amino acids 
with alanine particularly elevated. It is conceivable that the inter- 
ference with amino acid metabolism is aetiologically related to the 
Gray -baby syndrome. 
There is little doubt that the vacuoles seen in the bone marrow 
red cell precursors of the infants treated with chloramphenicol were 
the result of chloramphenicol toxicity. The vacuoles seen in the 
cytoplasm of myeloblasts, promyelocytes, myelocytes and metamyelocytes 
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were probably due to chloramphenicol but some reservations to this 
interpretation must be held in view of the presence of infections 
in these infants (Ponder and Ponder, 1942). Myeloid vacuoles appeared 
sooner and, at times, disappeared more rapidly on recovery than the 
erythroid vacuoles, as might be expected from the more rapid rate 
of myeloid cell turnover. 
The changes in circulating free amino acid concentrations 
suggest a block in the utilization of amino acids. Increased urinary 
excretion of these amino acids rules out the possibility that the 
elevations in plasma concentrations were due to primary renal dys- 
function produced by chloramphenicol. 
It was only shortly after the introduction of chloramphenicol 
for clinical use that scattered reports associated therapy with 
severe depression of the bone marrow resulting in aplastic anaemia 
or pancytopaenía (Welch et al, 1954). There is now no question that 
chloramphenicol can cause severe bone marrow depression with fatal out- 
come (Dameshek, 1960; DeNosagno, 1960; Krakoff, 1955). Of 169 deaths 
listed by the Registrar- General as being due to therapeutic mis- 
adventure in England and Wales during 1962, twelve deaths from blood 
dyscrasia were caused by chloramphenicol. Although the incidence 
of this complication is reported as 1 in 20,000 to 1 in 50,000 
patients treated with chloramphenicol, the incidence would probably 
be higher if a child population were analysed. This same report 
argues that chloramphenicol should be reserved solely for the treatment 
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of Typhoid. Many arguments have been raised about the efficacy 
of penicillin alone in the treatment of Haemophilus meningitis but 
the majority of paediatricians would still employ the well -tried 
and effective chloramphenicol with penicillin therapy. There is, 
likewise, a good argument for the use of chloramphenicol in Gram 
negative septicaemias in the neonatal period. Whatever the final 
outcome of such arguments might be, there is no doubt that the anti- 
biotic is a very effective one. If it were possible to remove the 
cellular toxicity to the host and yet maintain an effective anti- 
biotic action, there would be great advantage. 
Chloramphenicol and Phenylalanine: Study 2b demonstrates the 
reversal of marrow vacuolization in four chloramphenicol treated 
infants given L- phenylalanine, 100 mg /kg /day, orally while chloram- 
phenicol therapy continued. Phenylalanine was not given to these 
infants until at least three days of effective chloramphenicol treat- 
ment had been completed. The doses of L- phenylalaniue were approxi- 
mately equal on a molar basis with those of chloramphenicol and the 
duration on this regimen perforce short. Nonetheless, the effects 
were dramatic in these four infants. 
The interaction of phenylalanine and chloramphenicol in relation 
to mammalian protein synthesis and bacterial growth is one of great 
interest but its significance inftherapeutic situations remains to 
be proven. Woolhy (1950) proposed that the antibiotic could be 
regarded as a metabolic analogue of phenylalaniue and the similarity 
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of chemical structure is apparent in Fig. 4, p. 31. Yamada et al, 
1963, have used L- phenylalanine as a basis for the synthesis of chlo- 
ramphenicol. 
More recently, Jardetsky (1962 and 1964) has shown that the 
steric configuration of chloramphenicol in solution is very similar 
to uridine 5' phosphate. he suggests that the site of action of 
chloramphenicol is on the ribosome and that it acts by interfering 
with uridine coding. The genetic code for phenylalanine,as carried 
by messenger RNA to the ribosome, is a triplet of uridylic acid [UUU] 
or two uridylic residues with one cytodylic [UCU] (Bernfield and 
Nirenberg, 1965). Thus, any interference with uridine should, in 
theory, preferentially inhibit the incorporation of phenylalanine 
into protein. 
Gale, 1958, has demonstrated that chloramphenicol interferes 
with synthesis of both protein and nucleic acid in vitro. his experi- 
ments showed that this interference leads to the accumulation of 
glutamic and adenine -labelled substances which, he though represented 
a piling up of biosynthetic precursors whose utilization had been 
blocked by chloramphenicol. These substances have not been identified 
but possibly represent an amino -acyl nucleotide complex, a precursor 
of nucleoprotein synthesis. Wnen chloramphenicol is removed from an 
inhibited bacterial culture, the material which accumulates in the 
presence of chloramphenicol will then be incorporated in more complex 
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molecules. It is interesting to speculate that the red cell pre- 
cursor vacuoles described in patients treated with chloramphenicol 
might contain substances analogous to those demonstrated by Gale 
in bacterial culture. An analysis of the vacuole "content" in the 
phenylalanine deficient and chloramphenicol treated red cell pre- 
cursor by radio -autographic or other techniques is an obvious step 
in the further elucidation of the blocking mechanism involved.J. The 
main limitation to this study is the lack of a suitable experimental 
animal which will readily show vacuoles in the red cell precursors. 
Rhesus monkeys will show changes in their marrow similar to that of 
the human infant when given large doses of chloramphenicol (Weiss, 
1965), and would be an obvious choice of animal for such a study. 
Whatever the final mechanism, study 3 suggests that parenteral 
L- phenylalanine given in a dose equivalent to that of the chloram- 
phenicol will not inhibit the drug's antibacterial activity in the 
experimentally infected mouse treated with a single injection of the 
antibiotic. Indeed, there is a potentiation of the host resistance 
to Kiebsiella infection. This is not a direct effect of the amino 
acid since phenylalanine by itself had no demonstrable antibiotic 
activity. A preferential uptake of phenylalanine by the host cells 
might block the site of activity of chloramphenicol on the host cells 
and yet allow a more effective antibacterial concentration of chlo- 
ramphenicol outside the host cells. Another possible explanation is 
that this dose of phenylalanine might prevent the inhibitory effect 
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which chloramphenicol has on some protein dependent body defence 
mechanism such as antibody formation (Ambrose and Coons, 1963; Weis- 
berger and Wolfe, 1964; Daniel et al, 1965). The relevance of the 
findings in Study 3 to infections with organisms other than Kiebsiella 
pneumoniae or to human infections remains to be established. 
Chloramphenicol Toxicity and Diet: In early studies by Reutner 
et al, 1955, on the toxic effects of chloramphenicol on the bone 
marrow of dogs, it was thought that the effect was in large part due to 
an appetite depressant action of the drug. It is known that in the 
protein deficiency state found in kwashiorkor bone marrow depression 
and cytoplasmic vacuolization of red cell precursors will occur. The 
chloramphenicol toxicity in the dogs was prevented by feeding extra 
quantities of meat. There is evidence, apart from these early dog 
studies, that chloramphenicol has a greater depressant effect on bone 
marrow in protein deficient states. A study is at present being con- 
ducted in Thailand where there is an unusually high incidence of 
aplastic anaemia in children, and whew combined chloramphenicol therapy 
and protein deficiency are thought to be involved (Weiss, 1965). 
Vacuoles were present in the cytoplasm of the red cell precursors of 
a fourteen year old girl who had the nephrotic syndrome and who had 
been treated for four weeks with a small dose (25 mg /kg /day) of chlo- 
ramphenicol. She was found to have a low total protein and an 
altered albumin /globulin ratio. L- phenylalanine reversed her bone 
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marrow vacuolization. Elderly people tend to be relatively protein 
deficient and Scott et al, 1965, report that in the group they studied 
for evidence of chloramphenicol block in their ferrokinetic studies, 
it was probable that a dietary protein deficiency was the aetiologic 
factor in the greater sensitivity of some of their older patients to 
this toxic action of chloramphenicol. The findings presented indicate 
that chloramphenicol should not be used in any situation where there 
is severe malnutrition or protein deficiency states. 
Testosterone has been widely used in the treatment of aplastic 
anaemia and the reason for its occasional beneficial activity is 
unknown. It may be that it has a direct effect on phenylalanine 
incorporation into protein (Silverman et al, 1963) or it may be that 
its anabolic activity increases the intake and utilization of protein. 
There is a good argument for trying the effect of combined L- phenyla- 
lanine, testosterone and high protein diet in any instances of aplastic 
anaemia caused by chloramphenicol. It may be that by the time the 
aplastic stage has been reached, an irreversible change has occurred 
which is a cogent argument for restricting the use of chloramphenicol 
and for ensuring a very close patient follow -up with bone marrow and 
serial serum iron studies. 
Phenylketonuria: Much has been written about this inherited 
disorder and the description in Study 5 of two very young infants 
with the condition serves to underline the importance of early diagnosis 
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and the need for strict control of the diet. The morbidity and 
mortality from therapy, as well as from the disease itself, can be 
overcome by good dietary control. Pteridine derivatives may prove 
of value in the management of the young infant with the disease as 
described in Study 6, but attention must first be directed to ensuring 
adequate facilities for diagnosis and dietary management. 
The future will pose major problems in the management of the 
pregnancy of the girl with phenylketonuría who has reached maturity 
with no physical or mental stigmata of the disease because of careful 
dietary management during her early formative years. It remains to 
be shown that we can effectively reduce blood concentrations of 
phenylalanine in the pregnant woman with the disease and, at the same 
time, ensure adequate nutrition for the developing foetus. This is 
a problem which requires urgent consideration if we wish to be in a 
position to offer effective advice and care to mother and foetus. 
Phenylalanine: Foy and Kondi (1964) noted bone marrow changes 
and anaemia in infants with the clinical picture of kwashiorkor which 
are identical with those found in infants made deficient in phenyla- 
lanine. It may be that the vacuoles produced in kwashiorkor are the 
result of phenylalanine- deficiency per se but are more likely to be 
due to a failure of protein synthesis. This inability to manufacture 
new protein because of a deficiency of one or of many essential amino - 
acids is true of the situation found with chloramphenicol toxicity, 
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where the machinery for making normal new protein is blocked. All 
the clinical situations where cytoplasmic vacuoles in the erythrogones 
are described have in common a relative insufficiency of new protein 
formation. In DiGuglielmo's syndrome, it is probable that the ex- 
treme rapidity of red cell precursor proliferation outstrips the 
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available supplies of amino acidÀnucleic acid. 
Of course, it is not only a deficiency of an individual amino 
acid which can cause a block to protein synthesis. An excess of 
phenylalanine, for example, can inhibit new protein synthesis in the 
infant with phenylketonuria just as it can inhibit antibody formation. 
in the experimental animal (Ryan, 1965) or leukaemic white cell 
proliferation in children (Allan et al, 1965). 
Protein synthesis can thus be Limited in the normal and the 
abnormal blood cell by an increase or a decrease of one dietary amino 
acid, or by a drug such as chloramphenicol which prevents the incor- 
poration of one or more amino acids into new protein. The influence 
of diet on the activity of the bone marrow and cells of the reticulo- 
endothelial system requires close attention as does the interaction 
of diet and drugs on the developing foetus and newborn infant. 
Disturbance of protein formation through interference with the 
amino acid phenylalanine can produce profound changes in tissue 
function. Only a few aspects of such changes have been explored in 
this thesis. 
SUMMARY 
Phenylalanine is an essential amino acid and as such is a 
necessary dietary constituent for the human infant. A short term 
dietary deficiency of phenylalanine in the normal infant is shown 
to lower the blood phenylalanine concentration to very low values 
within a period of forty -eight hours and at the same time, produce 
vacuoles in the cytoplasm of red and white cell precursors in the 
bone marrow. These changes are rapidly reversed by re- introdu- 
phenylalanine the diet. 
Chloramphenicol is an antibiotic which inhibits bacterial 
growth by blocking protein synthesis. It is shown to have a 
marked effect on the blood amino acid concentrations of young 
infants treated with chloramphenicol for a variety of infections. 
A possible relationship between the hyperaminoacidaemia with 
increased aminoaciduria and the "Gray- baby" syndrome is discussed. 
Bone -marrow changes identical with those caused by phenylalanine 
deficiency were produced in the infants by chloramphenicol and in 
four infants studied, these changes were reversed by increasing 
the dietary intake of L- phenylalanine in spite of continuing 
chloramphenicol therapy. 
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When mice are experimentally infected with Klebsiella pneumoniae 
then given equimolar quantities of chloramphenicol and L- phenylala- 
nine simultaneously, there is a potentiation of the antibiotic effect, 
but when the concentration of phenylalanine greatly exceeds that of 
the chloramphenicol, the antibiotic efficacy is markedly reduced. 
Two infants with phenylketonuria diagnosed in the first weeks 
of life are described. Their dietary management and the effect of 
a too severe dietary restriction on haematopoiesis and growth are 
described in detail. These two infants had cytoplasmic vacuolisation 
of their erythrogones when their blood phenylalanine levels were 
lowered below normal concentrations. 
Rats force -fed a phenylalanine deficient diet or given paren- 
teral chloramphenicol did not produce cytoplasmic vacuoles in their 
marrow red cell precursors but there was some reduction in marrow 
cellularity. Tritium labelled alanine, phenylalanine and uridine 
failed to show any particular localisation in bone -marrow radio - 
autographs from these animals. 
Phenylalanine tolerance tests were performed on four children 
with phenylketonuria. Folinic acid administered with the oral 
phenylalanine load had no demonstrable effect on the two older 
children so treated. Two infants, however, showed a marked reduc- 
tion in blood phenylalanine concentrations when given folinic acid. 
The possible value of a tetrahydrofolic acid derivative in 
the management of the very young infant with phenylketonuria is 
discussed in relation to the difficulties earlier described in the 
dietary management of the disease. 
The final discussion reviews the role played by phenylala- 
nine in infant nutrition and disease. 
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APPENDIX I 
Case Histories of Four Patients with Phenylketonuria. 
J.M. - This infant, an 18 day old Caucasian male, was 
admitted to the Pediatric Clinical Research Center in 'Boston 
when an elevated blood phenylalanine concentration (15.5 mg. ï) 
was detected at the four -day routine Guthrie screening test. he 
was born at term by spontaneous vertex delivery following a 
normal pregnancy to a 35 year old, gravida 3, para 3, white 
female. Birth weight was 2.8 kg. and there were no abnormalities 
detected during his four day stay in the Newborn Nursery. Fie 
was discharged home on the 5th day, feeding well on a modified 
milk preparation (Enfamil). 
The mother is well and gave no history of phenylketonuria, 
mental retardation or epilepsy in her family. This child's father 
is unknown as is his family history. There are two siblings; a 
girl aged 15 years and a boy aged 14 years, to a different father 
from J.H. Both children are doing well at school. The mother 
and two children all had negative urine ferric chloride tests and 
blood Guthrie tests. 
At the time of his admission to the ward for phenylalanine 
tolerance tests with and without folinic acid, he was six months old 
s 38, 
and weighed 6.6 kg. (3rd percentile). His crown -Heel length was 
64 cm. (10th percentile) and the head circumference measured 42 cm. 
(3rd percentile). he was, at this time, Fair- haired and blue -eyed 
with no gross neurological abnormalities. 
His haemoglobin was 11.5 G %, the haematocrit, 36% and the 
white blood cell count was 13,600 per cu. mm., 75% polymorph cells 
and 25% lymphocytes. Red cells and platelets were normal. 
A full description of the management and progress of this 
child is given on p. 37. 
LIT 
B.G. - This male infant was born -at 31 weeks gestation to 
a 25 year old Caucasian, gravida 6, para 4, mother who had an 
uneventful prenatal course until the spontaneous rupture of membranes 
and premature delivery. Birth weight was 1.76 kg. and there were 
no physical abnormalities detected at routine examination. pie was 
fed a modified cow's milk preparation (Enfamil) from 24 hours. On 
the fourth day of life, mild clinical icterus, consistent with 
"physiologic icterus neonatorum," developed. At 6 days, a mouilial 
infection involving mouth and napkin region developed and he was 
treated for 14 days with 200,000 units of nystatin. daily by mouth. 
The oral lesions resolved in 4 days but the rash persisted after 
therapy was discontinued. 
At 23 days of age, a positive Guthrie bacterial -inhibition 
assay test for phenylketonuria was reported by the Diagnostic Labo- 
ratories of the Massachusetts Department of Public health. A stL- 
sequent urinary phenistix test was positive as was the ferric chloride 
test for phenylketonuria. 
The serum phenylalanine concentration at this time was 42 mg/ 
100 ml. as determined by the Lau method (La_u, 1963). Phenylalanine 
loading tests were carried out on both parents who were found to 
be heterozygous for the phenylketonuria trait. The patient's siblings 
were tested by the Guthrie and Phenistix tests, and the two olner 
children were negative, but a 17 month old sister, J.G., had a 
40. 
positive Guthrie test and a blood phenylalaníne level of -37 mg/ 
100 ml. 
Two maternal cousins had died in the first two years of life 
but there was no other relevant family history. 
At the time of his admission to the ward for phenylalaninc 
tolerance tests with and without folinic acid, he was 16 months 
old and weighed 8.0 kg. (50th percentile for 7 months). his length 
was 70 cm. (50th percentile for 9 months) with a head circumference 
of 46 cm. (50th percentile for 9 months). he was fair -haired and 
blue eyed with no major neurological abnormalities apart from 
developmental retardation. he was able to walk with his 
haemoglobin was 11 G per 100 ml. with a haematocrit of 32%, an6 
a white cell count of 8,350 per cu.nim. with 60; polymorphs, 33% 
lymphocytes and 2. monocytes. Red cells were normocytic and nomo- 
chromic and platelets were plentiful. Tne tuberculin skin test 
was negative. 
A full description of the management and progress of this 
child is given on p. 92. 
4 -ate % 
/41. 
T.G. - This infant was diagnosed at the age of 17 months 
as having phenylketonuria at routine family screening when her 
brother (B.G.) was found in the newborn period to have phenyiketo- 
nuria. 
She was a normal full term baby with a birth weight of 2.4 kg. 
For family history, see B.G. During the first year of life, her 
weight gain was satisfactory but was described as a very irritable 
infant. At one year, she was unable to roll over and was unable 
to sit unsupported. At 17 months, a low phenylalanine diet was 
started and there was, according to her mother, a marked improve- 
ment in her disposition. By 24 months, she was walking and saying 
single words. her dietary intake of phenylalanine is controlled 
by frequent estimations of blood phenylalanine concentrations. 
At the time of admission to the ward for phenylalanine tole- 
rance tests with and without folinic acid, she was 33 months old 
and her weight was 12.2 kg., height 87.3 cm. (normal for 2 year 
old) and head circumference 47.3 cm. (normal for 15 months). her 
- complexion was fair with blond hair and blue eyes. The anterior 
fontanelle was not palpable. Neurological examination showed 
normal motor and sensory function with good coordination. Vocabu- 
lary was very limited for her age. 
Urinary ferric chloride tests at this time were negative and 
her blood phenylalanine concentration was 8 mg /100 ml. blood. 
Her haematocrít was 36% with a white blood cell count of 
7500 /cu. mm. with 56% polymorphs, 40% lymphocytes and 4% monocytes 
Red cells and platelets were normal. The tuberculin skin test 
was negative. 
C.B. - This child, a Caucasian female, was first admitted 
to hospital at the age of nine months because of failure to thrive 
normally. At that time, she smiled and lifted her head but had 
progressed no further in her development. her blood phenylalanine 
concentration was found to be 32.3 mg. % and h.er urinary ferric 
chloride test for phenylketonuria was positive. Although treatment 
with a low phenylalanine diet was instituted, control has never 
been satisfactory due to poor cooperation on the part of her mother. 
She was born at term following a normal pregnancy and delivery 
to a 30 year old, gravida 4, para 4, white female. Birth weight 
was 3.0 kg and there were no clinical abnormalities noted during 
the newborn period when she fed on a modified milk preparation 
(Enfamil) . 
Both parents are well with no consanguinity. The three sib- 
lings are in good health with negative urinary ferric chloride and 
blood Guthrie tests. There is no other positive relevant family 
history. 
At the time of admission to the ward for phenylalanine tolerance 
tests with and without folinic acid, she was 3 years and 9 mouths 
old. Her weight was 15.8 kg. and her height was 100.5 cm., both 
within normal limits for her age, but her head circumference measured 
47.5 cm. which is normal for 18 months and in the 10th percentile 
for a 3 year old. Neurological examination showed a moderately 
 4E*. 
cooperative child who babbled and would speak two word 'sentences' 
to her mother. There was good muscle strength and tone with good 
coordination, normal tendon reflexes, flexor plantar responses arid. 
normal sensation. 
Urinary ferric chloride tests were positive on admission 
but after 7 days on her prescribed diet containing 375 mg. of 
phenylalanine per day these became negative. her haemoglobin was 
11.3 G % with a haematocrit of 35 %, and a white cell count of 
8,650 per cu. mm. with 73% polymorphs, 26% lymphocytes, 1% mono - 
cytes and 1% basophil cells. Red cells and platelets were normal. 
Tuberculin skin tests were negative. 
APPENDIX II 
In studies I and II, determinations of the amino -acid content 
of plasma, serum or milk preparations were carried out using the 
"Technicon" Amino Acid Analyzer Adaptation of the technique des- 
cribed by Spackman et al, 1958. The column diameter for these 
estimations was 6 mm. and a 1.0 ml. sample of serum or plasma 
was required to ensure a single accurate analysis. For the sub- 
sequent studies which required frequent analyses of blood amino 
acid content in small infants the following micro -technique was 
employed. This technique allowed the analysis of whole blood 
amino acids to be performed on 0.2 ml. of blood obtained by 
heel or finger prick. 
METHOD: The details of the apparatus and ion -exchange resin 
used have been previously described by Hamilton, 1963. 'Technicon' 
Corporation supplied two jacketed columns of 1/8 th inch internal 
diameter. The two columns were operated simultaneously and at a 
temperature of 60° C. The gradient of sodium citrate buffer from 
pH 2.875 to pH 5.0 was supplied from separate 'Autograds' and 
pumped by separate 'Milroy' micro pumps. Effluent buffer and 
amino acids from each column were mixed with a solution of ninhydrin 
and hydrindantin in methyl cellusolve, segmented with nitrogen 
and colour developed in an oil bath at 95 °C. After cooling, the 
final effluent was monitored through separate photo- electric 
cells filtered at 570 wavelength. At this wavelength proline 
and other amino acids which develop a yellow colour with ninhydrin 
could not be accurately determined. For this particular group 
of analyses this proved no inconvenience but the addition of a 
second colorimeter with a 460 filter would allow a complete 
amino acid analysis. The intensity of colour developed by each 
amino acid with the ninhydrin automatically recorded as an optical 
density on logarithmic ruled paper. Fig. 21 is part of an actual 
tracing obtained by this micro technique from 0.2 ml. samples of 
whole blood. The tracing obtained from a capillary whole blood 
sample of a phenylketonuric infant is compared with the blood 
amino acid profile of a normal infant. A complete analysis of 
two samples takes twenty -two hours to completion. Quantitative 
determination of the individual amino acid content is readily 
obtained by measurement of the area of each peak and comparing it 
with the peak area of a known amount of standard pure amino acids. 
The total error for the method is + 5 %. 
Heparinised capillary whole blood and venous plasma samples 
were obtained from five children and analysed by this method. 
Fig. 21 
Part of the Amino Acid profile obtained from 
the blood of a phenylketonuric infant (orange) 
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COLLECTION OF SAMPLES: Approximately 1.0 ml of venous blood 
from each of five children was collected into sodium heparin con- 
taining tubes. After careful skin preparation and immediately 
after collection of the venous sample free -flowing finger or heel 
prick, capillary blood was collected into a capillary tube con- 
taining dried sodium heparin. 
PREPARATION OF SAMPLES FOR ANALYSIS: The venous blood was 
centrifuged for ten minutes. 0.3 ml supernatent plasma was added 
to 0.3 ml ion -free distilled water and 0.3 ml of 0.6 M Sulpho- 
salicylic acid was then added, mixed thoroughly and allowed to 
stand for 15 minutes. Recentrifugation packed the precipitated 
proteins and 0.6 ml of the supernatent was applied directly to 
one column for analysis. 
A volume of 0.2 ml heparinised capillary whole blood was 
measured accurately immediately after collection and mixed with 
4.0 ml of 0.05% Saponin solution. After standing for 10 minutes, 
1.0 ml of 15.6% Trichloracetic Acid (TCA) was added (final con- 
centration of TCA = 3 %) mixed thoroughly and allowed to stand for 
15 minutes. After centrifugation, 4.0 ml of the supernatent was 
transferred to a clean test -tube and completely dried in an air 
stream. The sample could then be stored dry at -68 °C or recon- 
stituted with 0.6 ml ion -free distilled water. 0.5 ml of this 
solution was applied to the second column. 
RESULTS: Table XIV shows the amino acid concentrations in 
capillary whole blood and plasma of five children. The mean values 
agree fairly well with a few exceptions though the small number 
does not allow a good statistical analysis. 
COMMENTS: A good review of the techniques of handling blood 
for amino acid analysis is given by Dickinson et al, 1965. They 
found that plasma obtained by heel prick had a higher concentra- 
tion of taurine, glutanic acid, glycine, alanine and ornithine 
than femoral vein plasma obtained at the same time. 
Some possible sources of difference between the values given 
in Table XIV are the increased quantities of glycine, alanine and 
ornithine present on skin surfaces (Hamilton, 1965). The higher 
concentrations of some amino acids in red and white blood cells 
and tissue fluids from the heel punctures will also contribute to 
a different concentration of amino acids in whole blood when com- 
pared to the plasma of the same individual (Soupart, 1962, 
McMenamy et al, 1960). 
For practical purposes, capillary whole blood concentrations 
of amino acids are adequate for the detection of hyperaminoacidaemia 
and for the regulation of dietary management in the phenylketonuric 














































































































































































































































































































































































































































































































































































































































































































































































































































































time consuming for routine screening of newborn infants. The 
method is ideal,however, as a research tool and can give accurate 
amino acid analyses on 0.5 -1.0 ml samples of saliva, sweat or 
cerebrospinal fluid. 
